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Chapter 1 
 
General Introduction 
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Down syndrome 
 
Down syndrome (DS) (MIM 190685), described by Down in 1866, is by far 
the most common and best known chromosomal disorder in humans with a 
frequency in the general population ranging from 1:650 to 1:1,000 live births 
and 1:150 conceptions (Hook 1982). Mental retardation, dysmorphic facial 
features and other distinctive phenotypic traits characterize the syndrome but 
the DS phenotypes are often variable among subjects.  
DS, caused by trisomy of either the entire or a critical portion of chromosome 
21 (21q22.1-21q22.3), occurs in 95% of cases as a result of meiotic 
nondisjunction (NDJ) mainly of maternal origin and in 2 to 4% of cases as a 
mosaicism of trisomic and normal cells (mitotic non-disjunction) 
(Antonarakis et al., 1991; Antonarakis et al., 1992; Antonarakis et al., 1993; 
Sherman et al., 1991). 
In about 5% of patients, chromosome 21 is translocated to another acrocentric 
chromosome, most often chr 14 or 21. 
 
 
1. Etiopathogenesis: The origin of the extra copy of 
chromosome 21 
 
Trisomy 21 is due in 95% of cases to full trisomy 21 caused by meiotic non-
disjunction or abnormal segregation of chromosomes occurring mainly during 
maternal oogenesis (95%) (Antonarakis, 1991; Freeman et al., 2007), 
particularly at meiosis I (MI) (80%) (Antonarakis, 1992; Sherman et al., 
2007). 
The age of the mother at the time of the conception is, by far, the most 
significant risk factor for having a fetus with DS. In fact, the birth prevalence 
increases with maternal age from 0.6 in 1,000 live births at maternal age of 20 
up to 11 in 1,000 live births at maternal age of 40 (Morris et al., 2003).  
Aside from maternal age, an association between maternal non-disjunction 
errors and reduced recombination along chromosome 21 was suggested 
(Warren et al., 1987). Furthermore, some studies have shown that not only the 
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absence but also the site of the exchanges is an important susceptibility factor 
for non-disjunction (Lamb et al., 1997). A single telomeric exchange leads to 
an increased risk for MI error, whereas pericentromeric exchanges increase 
the risk for MII error (Hawley et al., 1994). 
More recently, the relationship between maternal age and recombination has 
been explored in order to further elucidate the causes of chromosomal NDJ 
(Lamb et al., 2005; Oliver et al., 2008). 
The process of oogenesis is lengthy and involves meiotic arrest, which makes 
it more vulnerable to malsegregation of chromosomes than spermatogenesis 
(Oliver et al., 2008). Moreover, with increasing age, there is rapid 
degradation of cellular proteins involved in spindle formation (Hawley et al., 
1994), sister chromatid cohesion (Wolstenholme and Angell, 2000) or 
anaphase separation of sister chromatids in oocytes, which imposes the risk of 
NDJ both at MI and MII (Yoon et al., 1996). 
Recombination, initiated in the fetal ovary, stabilizes the tetrad and ensures 
proper segregation of chromatids to opposite poles. But the process is random 
and may be absent even in euploid samples (Cheung et al., 2007). These 
achiasmate meioses are at risk for NDJ, and this risk increases with age due to 
rapid deterioration of ovarian proteins that control the separation of these 
non-exchange chromosomes (Cheslock et al., 2005).  
It has been shown that nondisjoined chromosomes often show altered patterns 
of recombination (MacDonald et al., 1994; Hassold et al., 1995; Koehler et 
al., 1996b) and for trisomy 21, achiasmate meioses contribute about 45% of 
maternal MI cases (Sherman et al., 2007). Therefore, for MI errors, a greater 
proportion of single telomeric exchanges, within the distal region was showed 
by younger mothers while for MII cases, older age group mothers revealed a 
preferential occurrence of single chiasma within the proximal 5.2 Mb of 21q 
(Oliver et al., 2008). 
In conclusion, chromosomal NDJ is a complex and multi-factorial event for 
which the underlying mechanisms are related to two different sets of factors; 
one age dependent and another age independent. 
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1.1 Polymorphisms of genes involved in homocysteine/folate metabolism 
and risk of Down syndrome offspring 
 
Despite huge efforts, the mechanisms underlying meiotic nondisjunction and 
the maternal age effect on trisomy 21 are not completely understood. 
Recently, genetic and metabolic risk factors have been studied in human 
chromosome non-disjunctions and in particular a relationship between 
trisomy 21 and maternal polymorphisms in genes of folate and homocysteine 
metabolism have generated considerable interest. James et al., (1999) were 
the ﬁrst to propose the hypothesis that altered DNA methylation patterns 
resulting from abnormal folate metabolism may increase the risk of 
chromosome nondisjunction and in particular, suggetsed maternal 
polymorphisms in enzymes involved in this metabolic pathway as a risk 
factor for DS.  
Methylenetetrahydrofolate reductase (MTHFR) is one of the most important 
enzymes in folate/homocysteine metabolism. It is responsible for the 
conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate 
and regulates the intracellular ﬂow of folate through the conversion of 
homocysteine to methionine for nucleotide synthesis. This reaction is 
important for the synthesis of S-adenosylmethionine (SAM), the major 
intracellular methyl donor for DNA, protein and lipid methylation. 
 Two polymorphisms (C677T and A1298C) in the MTHFR gene affect this 
pathway by reducing enzyme activity (Frosst et al., 1995; Van der Put et al., 
1998), leading to an increased need of folic acid to allow the remethylation of 
Hcy to Met. An increase in Hcy levels associated to a decrease in methionine 
results in a decreased SAM to S-adenosylhomocysteine (SAH) ratio whose 
optimal value, known as methylation index (10:1) is required for a correct 
functioning of the methylation machinery (Round et al., 1998). Recently, a 
third common mutation of the MTHFR gene (G1793A) has been described 
but its effect on the folic acid metabolism is still unknown (Rady et al., 2002).  
The remethylation of Hcy to Met is catalysed by the methionine synthase 
(MTR) enzyme, maintained in its functional state by the methionine synthase 
reductase (MTRR) reducing system. Two polymorphisms have been 
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described in the MTR and the MTRR genes, A2756G and A66G respectively, 
and the former has been associated with aberrant methylation in the 
homozygous state (Castro et al., 2004).  
Furthermore, the mutation 844ins68 in the cystathionine beta-synthase (CBS) 
gene, reported by our group as a common polymorphism in the general 
population and carried by nearly 10% of the general population (Sebastio et 
al., 1995; Sperandeo et al., 1996; De Franchis et al., 2002), may affect Hcy 
levels and cause lower tHcy levels compared to non-carriers, in particular 
after methionine loading (Tsai et al., 1997). 
Other mutations of genes involved in Hcy and folate metabolism include: 
A80G in the reduced-folate-carrier gene (RFC1), associated with higher 
plama folate levels and moderate hyperhomocysteinemia if in double 
homozygous with MTHFR 677TT genotype, and G1958A in the 
methylenetetrahydrofolate dehydrogenase gene (MTHFD), which encodes for 
a trifunctional enzyme that catalyses the conversion of tetrahydrofolate to 10-
formyl, 5,10-methenyl, and 5,10-methylenetetrahydrofolate, donor cofactors 
for nucleotide and DNA biosynthesis (Chango et al., 2000). 
James and coworkers were the first to report that the variant 677T allele of 
the MTHFR gene might be a maternal risk factor for having a child with DS 
in a North American population, and observed increased plasma Hcy levels in 
mothers of DS individuals (MDS), compared to mothers of healthy children 
(James et al., 1999).  
After these studies, a number of research groups focused on case–control 
studies to further investigate the effect of folate pathway polymorphisms as 
possible risk factors for DS. 
Some of these studies reported an association between maternal 
polymorphisms and trisomy 21 (James et al., 1999; Hobbs et al., 2000; 
O’Leary et al., 2002; Da Silva et al., 2005; Scala et al., 2006), whereas others 
could not ﬁnd any association (Chadefaux-Vekemans et al., 2002; Stuppia et 
al., 2002; Bosco et al., 2003). 
Another complexity to our understanding of the role of folate metabolism in 
DS risk is the fact that several metabolic genes, including those encoding for 
the reduced folate carrier (SLC19A1 or RFC1) and for cystathionine beta 
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synthase (CBS), are located on chromosome 21. Trisomy for these genes 
might increase folate demand or availability in developing DS fetuses. 
Therefore, the current opinion is that maternal and embryonic combinations 
for variants in folate metabolizing genes, coupled with the maternal 
nutritional and life style status during pregnancy, may strongly influence the 
probability that some embryos with trisomy 21 survive to the birth (Martínez-
Frías et al., 2006). 
Furthermore, the contribution of maternal age at conception adds complexity 
to the investigation of the role of folate metabolism in DS risk and emphasize 
the fact that human non-disjunction is a multifactorial trait that must be 
dissected into its component parts to identify specific associated risk factors 
(Lamb et al.,2005; Oliver et al., 2008; Hultén et al., 2008) 
The discordant data among subjects of distinct geographical regions may be 
explained by differences in the nutritional habits, genetic background of the 
populations, ethnicity. Furthermore, the conflicting results suggested that the 
presence of a single polymorphism of a gene participating in the folate/Hcy 
metabolic pathway might be insufficient to increase the risk of having a child 
with DS, whereas the combined presence of two or more of them in the 
genome could increase DS risk. 
 
 
 
2. The phenotypic variability of Down syndrome 
 
Although caused in the majority of cases by full trisomy of chromosome 21, 
the DS phenotype is often variable among subjects. Almost all individuals 
show specific morphologic features, mental retardation and hypotonia that, 
taken together, constitute the hallmark of the syndrome. However, the degree 
of these clinical manifestation is largely variable and a wealth of other 
clinical manifestations occurs only in a proportion of subjects. Congenital 
cardiac anomalies, including ventricular septal defects, A/V communis, 
arterial septal defects, and patent ductus arteriosus, are present in about 40% 
of Down syndrome infants. Other congenital malformations include duodenal 
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stenosis or atresia (in about 10% of cases), congenital cataract, Hirschsprung 
disease. Down syndrome subjects also display immune-hematologic 
anomalies such as lymphopenia, impairment of cell mediated immunity and 
of serum immunoglobin patterns and increased susceptibility to dermal, 
mucosal, gastrointestinal and respiratory infections. Children with Down 
syndrome are also at greater risk of developing leukemia, usually the acute 
lymphocytic type, with an increase of 10-15 fold confined to the pediatric age 
group. Auto-immune and endocrine disorders such as hypothyroidism, gluten 
intolerance, diabetes, alopecia are also observed at increased frequency in 
Down syndrome compared to the general population. Finally, premature 
aging and early onset of Alzheimer’s disease are included among DS features. 
 
 
 
3. Metabolic imbalance in Down syndrome: 
homocysteine/folate metabolism, the oxidative stress and the 
mitochondrial dysfunction 
 
Although the perception of DS as a metabolic disease is not prevalent, 
overexpression of genes encoding specific enzymes directly leads to 
biochemical aberrations that affect multiple interacting metabolic pathways, 
culminate in cellular dysfunction and contribute to the pathogenesis of DS.  
A metabolic derangement of the Hcy/folate pathway and abnormal DNA 
methylation have been observed in children with DS, in whom a lack of 
active methyl groups and altered protein activity have been proposed as 
possible pathogenetic mechanisms of various manifestations, including 
mental retardation (Gueant JL et al., 2005; Butler C et al., 2006). In fact, at 
least six genes involved in the one-carbon/transulfuration pathway are 
mapped on chr 21, including: the cystathionine beta-synthase (CBS) gene; 
two folate transporter genes (RFC1 and FTCD respectively); the 
glycyneamide ribotide formyltransferase (GART) gene, involved in purines 
biosynthesis; a DNA methyltransferase 3-like gene (DNMT3L); and an 
arginine methyltransferase 1-like protein (HRMT1L1), involved in protein 
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post-translational methylation. 
A major point of interest relies in the study of metabolic impairment of the 
Hcy/folate pathway due to the 3 copies of the CBS and RFC1 genes and of 
the influence of polymorphisms on biochemical data. However, a wealth of 
studies points to a higher grade of complexity of the pathogenesis of DS 
including the gene-dosage effect of selected genes localized on chr. 21, signal 
transduction pathway impairment and mithocondrial dysfunction (Butler et 
al., 2006, Chang et al., 2005; Arron et al., 2006). 
In children with DS in whom the CBS gene resulted overexpressed with an 
activity increase of 157%, reduced Hcy levels were documented (Chadefaux 
et al., 1988, Chadefaux et al., 1985). Pogribna and coworkers (Pogribna et al., 
2001) evaluated that the three copies of CBS resulted in a significant decrease 
of plasma Hcy, Met, SAM, SAH while the lymphocyte DNA was surprisingly 
hypermethylated (Pogribna et al., 2001). 
Until now, there are no available data on the metabolic effects of the three 
copies of the CBS gene combined to polymorphisms of genes of the sulfur 
amino acid and folate pathway in patients with DS.  
An imbalance of the cell redox activity was suggested as another key player 
in DS pathogenesis. In fact, protein modifications by reactive oxygen species 
(ROS) may have a crucial role in the pathogenesis of a number of DS 
features, such as neurodegeneration, premature aging, autoimmune disease 
and cataract. However, there is no definitive consensus on whether OS is 
mediated by increased oxidation, decreased antioxidant levels, or insufficient 
clearance of oxidized proteins.  
In DS, markers of OS such as lipid peroxidation, protein modifications and 
DNA damage are increased as well as the gene expression of superoxide 
dismutase 1 (SOD1) and amyloid precursor protein (APP), both mapping on 
chr 21 (Zana et al., 2007, Galletti et al., 2007). Published data from our group 
showed a dramatic increase of L-isoaspartyl (L-isoAsp) residues in 
erythrocytes membrane proteins of DS subjects under basal condition and 
after oxidative treatment (Galletti et al., 2007). In proteins, L-isoAsp residues 
arise from deamidation of intrinsically labile L-asparagines, and might be 
related to cell ageing, impairment of cognitive function associated with 
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abnormal processing of amyloid beta precursor APP (Lott et al., 2006). 
As to the total antioxidant capacity, it was shown to be decreased in one study 
and preserved in another (Carratelli et al., 2001; Zitnanova et al., 2006). In 
particular, impairment of the glutathione redox state has been observed in DS 
subjects (Pastore et al., 2001; Michova et al., 2007). 
Both disruption of the sulfur amino acid pathway and oxidative damage can 
be related to mitochondrial dysfunction and may independently lead to 
impairment of the methylation machinery. Damage of mtDNA induced by 
enhanced oxidative stress in DS brains and fibroblasts (Busciglio J et al., 
1995, Busciglio J et al., 2002), can result in ATP depletion and interfere with 
DNA methylation, since the synthesis of SAM, the major intracellular methyl 
donor for DNA, is a high-energy form of methionine and requires ATP. Also 
the alteration of the one-carbon metabolism modifies the levels of SAM, 
leading to different methylation reactions also in mithocondria, in which the 
status is already defective in DS pathogenesis.(Arbuzova et al., 2002; 
Infantino et al., 2011) 
The mechanism and the cellular site (cytosol and/or mitochondria) 
responsible for the overproduction of ROS have not been fully elucidated. 
The up-regulation of the SOD1 gene, located on human chr 21 (Torsdottir et 
al., 2001; Sinha, 2005), has been proposed as a potential culprit. However, an 
animal model of DS, the TS1Cje mouse, carrying a subset of triplicated 
human chr 21 orthologs that lacks SOD1, shows OS and mitochondrial 
dysfunction (Shukkur et al., 2006). 
In fact, ROS are generated inside mitochondria by respiratory chain 
complexes I and III. Dysfunctions of these complexes, as well as of ATP 
synthase, can result either in reduced ATP levels or in increased ROS 
production (Raha et al., 2000) and were associated to neurodegenerative 
diseases such as Alzheimer's, Parkinson's and Huntington's diseases and in 
the normal aging process (Schon et al., 2003; Ames, 2004; Kidd, 2005; 
Gandhi et al., 2005).  
In human DS cells, gene expression variations of oxidative phosphorylation 
units Krebs cycle enzymes (Kim et al., 2000; Kim et al., 2001; Lee et al., 
2003; Bajo et al., 2002), reduced mithocondrial redox activity and membrane 
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potential (Busciglio et al., 1995), ATP depletion (Valenti et al., 2010), 
impaired mtDNA status and repair systems (Infantino et al., 2010; Druzhyna 
et al-, 1998) were described. 
 
 
 
4. Gene expression variation 
 
The simplest model for gene expression in DS would predict that each gene 
on chromosome 21 would be expressed at 150% of the levels seen in euploid 
individuals. A number of investigators have examined this question both in 
tissues or cell lines from human DS and in mice trisomic for regions of 
Mmu16 homologous to HSA21. In general, the outcomes of these studies 
seem to support the hypothesis that many HSA21 genes are expressed at the 
expected 150% of normal, but there are numerous exceptions, including 
genes on HSA21 that are not overexpressed at all or overexpressed by more 
than 150%. In some studies, only overall global chromosome 21 gene 
expression could be concluded to be overexpressed. That is, the set of HSA21 
genes taken together is overexpressed by 150%, but overexpression of 
individual genes could not be assessed in a statistically significant way (Mao 
et al., 2003). In some cases, expression levels of individual HSA21 genes 
appeared to differ in different tissues and cells (Li et al., 2006). In some 
tissues, HSA21 genes are overexpressed while in others these same genes are 
not overexpressed. A similar situation exists in the Ts65Dn mouse model of 
DS. In this case, expression of the trisomic gene GABPA protein is elevated 
only in brain and skeletal muscle (O’Leary et al., 2004). Clearly, an answer to 
whether or not each HSA21 gene is overexpressed, to what extent, in which 
tissues, and during which developmental stage is an exceedingly important 
information to have when attempting genotype –phenotype correlations. 
An additional level of complexity comes from the recent observations of 
extensive gene-expression variation among unaffected individuals (Storey et 
al., 2007; Cheung et al., 2003; Monks et al., 2004) and that some HSA21 
genes varying up to 40-fold among individuals (Prandini et al., 2007; Deutsch 
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et al., 2005; Antonarakis et al., 2004; Stranger et al., 2005). 
Therefore, some authors suggested that overexpressed genes in DS can be 
considered good candidates for the pathogenesis only if tightly regulated in 
euploid cells, and that may play a role in the constant features of the 
syndrome if tightly regulated also in DS, while they could be responsible of 
the variable phenotypic features if expressed with an intermediate value 
(Sultan et al., 2007; Prandini et al., 2007; Ait-Yahya Graison et al., 2007). 
 
 
 
5. Mechanisms underlying gene expression variation 
 
The inference of data from gene expression studies is complicated by the 
great number of factors that may influence gene expression besides trisomy 
21, such as copy number variations, transcription factors variation, conserved 
non-coding regions, post-transcriptional regulation, DNA methylation and 
gene-gene interactions (Patterson, 2007). 
 
 
5.1 Copy number variations. 
 Copy number variations (CNVs) can be defined as regions of the genome, 
often several kb or larger, that vary in copy number from individual to 
individual (Iafrate et al., 2004; Sebat et al., 2004; Hegele, 2007). Often, these 
CNVs contain genes. A recent study presents evidence that duplication of a 
region of HSA21 including the APP gene can lead to familial Alzheimer’s 
disease (AD) in five separate families. In these families, the duplication 
ranges from 0.58 to over 6 Mb (Rovelet- Lecrux et al., 2006). Importantly, a 
detailed phenotypic analysis of the five families in which this duplication was 
observed demonstrated that there was no clinical evidence of DS (other than 
the appearance of AD) (Cabrejo et al., 2006). This observation is consistent 
with the idea that trisomy of APP may explain, at least in part, the 
observation that persons with DS virtually always develop the 
neuropathology associated with AD, but that trisomy of APP is not sufficient 
 - 16 - 
to cause DS. However, there are four other genes in the smallest duplicated 
region reported in these families, and the level of gene expression was not 
reported. Thus, the conclusion that APP is the responsible gene is attractive, 
but not definitively proven yet. A recent report indicates that duplication of a 
4.3 Mb region of HSA21 containing slightly more than 30 genes causes a DS 
phenotype in three family members (Ronan et al., 2007). These family 
members had the facial gestalt of DS but had mild cognitive disability. Again, 
however, no measurement of the level of overexpression of the genes in the 
duplicated region was reported. Moreover, two genes hypothesized to be 
involved in the phenotype of DS, DSCR1 and DSCAM, were not included in 
the duplicated region. Thus, it appears that duplication of this region, while 
contributing to the phenotype of DS, is probably not sufficient to cause all the 
features of DS. Although these data implicate CNVs as a reason for variation 
in gene expression, a recent study estimates that single nucleotide 
polymorphisms detect about 84% of gene expression variability while CNVs 
capture about 17% (Stranger et al., 2007).  
 
 
5.2 Transcription Factors and Variability of Expression. 
 There are at least 25 genes on HSA21 that directly or indirectly regulate gene 
transcription (Gardiner, 2006). Many if not most of these function as parts of 
multiprotein complexes. Alterations in the relative abundance of members of 
a protein complex may affect its activity in ways that are difficult to predict. 
Moreover, many genes are regulated by sets of transcription factors acting in 
concert.  
 
 
5.3 Conserved Noncoding Regions. 
 As the essentially complete genomic sequences of mammals in addition to 
humans have become available, genomic sequence comparisons have 
revealed the existence of a large number of conserved non-coding regions 
(Dermitzakis et al., 2005). Conserved noncoding regions (CNCs) are not 
repetitive sequences and the vast majority are not transcribed (Dermitzakis et 
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al., 2005). HSA21 was the first chromosome completely analyzed for CNCs, 
and 2,262 were identified. Possible functions for CNCs include roles as cis- 
or trans-regulatory regions or elements required for chromatin or 
chromosome structure (Dermitzakis et al., 2004).  
 
 
5.4 Post-transcriptional regulation.  
As the discussion above demonstrates, assessments of transcript levels are 
crucial for understanding DS and other conditions. However, post-
transcriptional regulatory mechanisms clearly play important roles, since 
transcript levels do not always accurately reflect the levels of the proteins 
they encode. Some unexpected mechanisms of posttranscriptional regulation 
have been revealed by functional genomics studies.  
 
 
5.5 MicroRNAs.  
MicroRNAs (MiRNAs) are endogenous small RNA molecules of about 22 nt 
derived from larger transcripts (Bartel, 2004; Kosik and Krichevsky, 2005). 
Hundreds of miRNAs have been identified (Nam et al., 2005). They bind to 
the 30 UTRs of mRNA molecules and can interfere with mRNA translation 
or subject mRNA to degradation (Bartel, 2004; Bartel and Chen, 2004; Fahr 
et al., 2005; Maas et al., 2006). An intriguing hypothesis is that miRNAs 
serve to dampen translation of mRNAs rather than have an all or none effect. 
In this way, they may be able to exert more rapid and subtle modifications of 
protein levels than transcriptional control mechanisms (Bartel and Chen, 
2004; Kosik and Krichevsky, 2005). At least five putative miRNAs are 
encoded by genes on HSA21. Recent work shows that miRNAs constitute up 
to 5% of human genes (Niwa and Slack, 2007). Each miRNA may contribute 
to the regulation of expression of hundreds of mRNAs. It appears that 
miRNAs may be particularly relevant to regulation of genes in the nervous 
system, genes that control expression of other genes, e.g., transcription factor 
genes, or genes that control signaling. There is evidence suggesting that this 
mechanism of gene regulation is relatively rare for genes that are widely 
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expressed in many cell types, and that may be essential for cellular survival, 
for example, metabolic genes (Cui et al., 2007; Gaidatzis et al., 2007).  
 
 
5.6 DNA methylation. 
 DNA methylation is strictly speaking an epigenetic change, not a genetic 
change. However, it clearly plays a role in gene expression, and genes on 
HSA21 play a role in the phenomenon. Since DNA methylation is critical for 
meiosis, and recent experiments suggest that it may play a major role in 
memory formation, a brief discussion is included here. Methylation of the 50 
position of cytosines located in cytosine-guanosine dinucleotides resulting in 
m5C is the primary, if not the only, modification of mammalian DNA (Turek-
Plewa and Jagodzinksi, 2005). Generally, DNA methylation is thought to 
play a role in long-term silencing of gene expression, and to be critical for 
mammalian development (Turek-Plewa and Jagodzinksi 2005; Shames et al., 
2007). In some cases, tissue-specific DNA methylation may be important for 
tissue specificity of gene expression in mice (Song et al., 2005). In cancer, 
global genome hypomethylation is often observed as coupled with 
hypermethylation of specific genes, for example, tumor suppressor genes 
(Shames et al., 2007). It has been hypothesized that altered dietary folates can 
affect DNA methylation, and correlations have been drawn between folate 
deficiency and increased risk for many types of cancer (Kim, 2005). The gene 
encoding the reduced folate carrier, considered the primary protein 
responsible for cellular internalization of folates, is located on HSA21 
(Moscow et al., 1995). Thus, one could hypothesize that elevated levels of the 
reduced folate carrier protein might enhance cellular uptake of folates 
mitigating the effects of low folate, including the effects of low folate on 
DNA methylation. This might be related to the observed low incidente of 
solid tumors in individuals with DS (Patja et al., 2006). Recently, 
demethylation of methylated miRNA resulting in its activation has been 
observed in cancer cells (Lujambio et al., 2007). This finding implies a link 
between regulation of gene expression by DNA methylation and miRNA. 
DNA methylation is carried out by a family of DNA methyltransferase 
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(DNMT) enzymes. A member of this gene family, DNMT3L, is located on 
HSA21 (Aapola et al., 2000). The DNMT3L protein has significant homology 
to the DNMT3 DNA methyltransferases, but its DNA methyltransferase 
activity has not yet been demonstred. However, it interacts directly with 
DNMT3A. DNMT3L knockout mice are viable, but sterile. Study of these 
mice has shown that DNMT3L is required for establishment of maternal 
imprints during oogenesis. Moreover, it is necessary for normal 
spermatogenesis (Hata et al., 2006). It is difficult to extrapolate from 
knockout mice to the possible effects of trisomy of the DNMT3L gene in 
persons with DS. However, one could speculate that overexpression of this 
gene might alter meiotic DNA methylation and be related to aberrant 
chromosomal segregation and also to the sterility seen in men with DS.  
 
 
5.7 Interactions between genes.  
Overexpression of individual genes cannot be considered indipendently when 
one considers phenotype–genotype correlations. Recent evidence 
demonstrates that trisomy of two or more genes acts synergistically to affect 
phenotype. A well-developed example of this type of synergy is the 
accumulating evidence that elevated expressions of the DYRK1A and 
DSCR1 genes on HSA21 act synergistically to prevent the nuclear 
localization of the NFATc transcription factor (Arron et al., 2006). Thus, 
trisomy of either of these genes individually may not be sufficient to cause 
this dysregulation, but trisomy of both is sufficient to cause dysregulation. 
 
 
 
6. Chromosome 21 genes and Down syndrome phenotype  
 
An essential step in understanding how the genes on HSA21 lead to DS has 
been the publication of the virtually complete DNA sequence of the long arm 
of HSA21 (21q) and the annotation of this sequence (Hattori et al., 2000). 
Annotation of HSA21 is an ongoing process and, currently, about 430 genes 
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have been identified (http://chr21db.cudenver.edu/). Along with the 
increasing knwoledge of the HSA21 structure, an unexpected complexity in 
genome structure and in gene regulation emerged with profound implications 
for understanding genotype/phenotype relationships.  
A specific region approximately 5.4 Mb onchromosome 21 (21q22.3), named 
Down syndrome Critical Region (DSCR) (Delabar et al., 1993) has been 
found to be associated with several of the major DS phenotypes including 
hypotonia, short stature, facial dysmorphisms, and mental retardation (Olson 
et al., 2007; Roper and Reeves 2006), even if it was observed that trisomy of 
this region is necessary but not sufficient to cause the brain phenotype in the 
trisomic mouse model (Olson et al., 2007). 
Currently, two different hypotheses have been proposed to explain the DS 
phenotype: the "gene-dosage effect" and the "developmental instability" 
hypothesis. The first hypothesis postulates that the overexpression of specific 
chromosome 21 genes directly contributes to different aspects of the disease 
phenotype (Korenberg et al., 1990), while the alternative "developmental 
instability" hypothesis states that the expression of extra genes, regardless of 
their identity or function, globally disturbs the correct balance of gene 
expression in DS cells during development (Saran et al., 2003; Shapiro et al., 
2001). 
To determine which hypothesis applies to the etiology of DS, a number of 
investigators have examined this question both in tissues or cell lines from 
individuals with DS and in mice trisomic for regions of Mmu16 homologous 
to HSA21. Several methods have been used, including DNA microarray 
analysis, serial analysis of gene expression (SAGE), and, less commonly, 
qRTPCR or proteomic approaches. 
In mouse models of DS most of these studies reported a generalized 
overexpression of triplicated genes at the mRNA level (Amano et al., 2004; 
Lyle et al., 2004; Kahlem et al., 2004; Dauphinot et al., 2005), while studies 
performed on human trisomic tissues indicated apparently discrepant results 
with some studies essentially showing the selective overexpression of a 
limited subset of chr21 genes (Altug-Teber et al., 2007; ; Mao et al., 2003; 
Mao et al., 2005), whereas other studies describe a more generalized 
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transcriptional dysregulation (Conti et al., 2007; FitzPatrick et al., 2002; 
Gross et al., 2002; ; Lockstone et al., 2007; Tang et al., 2004; Rozovski et al., 
2007). 
In particular, among studies underscoring essentially the dysregulation of chr 
21 genes in DS, Mao et al., (2003 and 2005) reported that, in fetal cerebral 
cortex, heart, and primary cultures of cortical astrocytes, the most consistently 
dysregulated chr 21 genes, were those involved in mitochondrial function 
(ATP5O, ATP5J and MRPL39) metabolic pathways (oxidoreductase, NADH 
dehydrogenase), antioxidant defenses (SOD1, superoxide dismutase I), and 
extracellular matrix (COL6A1, Collagen type VI alpha I). In fibroblast and 
fetal hearts, Li et al., (2006) proposed hyperactive interferon signaling as 
candidate pathway for cell senescence and autoimmune disorders in DS, and 
abnormal purine metabolism for a potential role in cardiac defects (Li et al., 
2006). A partial overlap with their overexpression patterns of chr. 21 genes, 
was reported also in amniocytes and chorionic villus cells by Altug-Teber et 
al., (2007). 
In audult T cells from DS, the most consistent finding was the overexpression 
of the superoxide dismutase gene (SOD1), MHC DR beta 3 (HLA-DRB3), 
GABA receptor A gamma 2 (GABRG2), acetyltransferase Coenzyme, A 2 
(ACAT2) and ras suppressor protein 1 (RSU1) genes (Giannone et al., 2004). 
On the other hand, to support the “developmental instability” hypothesis, 
studies on amniocytes (FitzPatrick et al., 2002) and fetal hearts (Conti et al., 
2007) found a vast majority of differentially-expressed genes not located on 
chr 21. In particular, the authors found upregulation of extracellular matrix 
(ECM) genes including metalloproteases in both tissues, and down regulation 
of genes associated with growth factors and mitochondrial function in fetal 
heart where oxidative phosphorylation was indicated as the most affected 
pathway. 
In cultured trophoblasts, Rozovski and colleagues (2007) showed an 
association between trisomy 21 and various biological processes connected to 
oxidative phosphorylation, ubiquitin cycle, purine nucleotide biosynthesis, 
rRNA metabolism and Alzheimer disease.  
In post-mortem adult cortex (Lockstone et al., 2007) and in whole blood 
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RNAs (Tang et al., 2004), dysregulated pathways encompassing 
developmental, lipid transport, cellular proliferation, and transcriptional 
regulation genes were found. 
Finally, one microarray study on cell-free fetal mRNA from uncultured 
amniotic fluid supernatant samples (Slonim et al., 2009), identified a 
deregulation of genes mostly belonging to functional classes pertaining to 
oxidative stress, phospholipids, ion transport molecules, heart muscle, 
structural proteins, and DNA repair and suggested compounds related to 
oxidative stress and to potassium/calcium signalling. 
In conclusion, these contrasting results, deriving at least partly from 
differences due to tissue specificity, developmental stages and the applied 
experimental platforms, suggested that the two hypotheses are not mutually 
exclusive and that it is possible that the DS phenotype is caused in part by 
genes that are over-expressed from chromosome 21, and in part by a 
generalized dysregulation. 
Recently, to extract more consistent and uniform informations, Vilardell et 
al., (2011) performed a statistical meta-analysis from 45 heterogeneous 
publicly available DS data sets, from human and mouse, at transcriptome and 
proteome level. The authors identified 324 genes with significant genome-
wide dosage effects, including 77 HSA21 genes such as SOD1, APP, RUNX1 
and DYRK1A, and 247 genes located on other chromosome, highlighting the 
genome-wide impact of DS. Pathway analysis, performed on all the 324 
significant genes, referred mainly to nervous system development, 
neurodegeneration (e.g. Huntington's disease, Alzheimer's disease or 
Parkinson's disease) and defects in synapsis (e.g. Axon guidance, NGF 
signaling), while Gene Ontology analysis of the 247 non-HSA21 genes 
revealed their association to human development (organ, tissue and cell 
development). Additionally, 70 different transcription factors, identified as 
being, directly or indirectly, affected by dosage imbalance, resulted 
associated to neurological development, organ development and stress 
response. Finally, 62 new genes, associated to neurodegenerative disorders 
including Alzheimer's disease and age-related degeneration, were identify as 
novel candidates. 
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However, this comparison have some limitations since the probes for the 
orthologous mouse and human genes do not correspond well and genes 
associated to nervous system might be over-represented, being the brain the 
dominant sample source. 
 
 
 
7. EXPERIMENTAL BACKGROUND 
 
Genome-wide expression analysis of lymphoblastoid cell lines from subjects 
with Down syndrome 
 
In the last years our group investigated the gene expression profiles of DS 
lymphoblastoid cell lines by DNA microarray analysis. Affymetrix HU133 
plus 2.0 oligonucleotide arrays containing 47,000 probe sets allowed us the 
screening of about 38,500 well characterized human genes.  
The expression values of the RNA derived from 6 DS subjects and 6 controls 
were determined using the Affymetrix GeneChip software v. 5.0 and then 
normalized to the values of the entire microarray by the GeneSpring software 
(Silicon Genetics, Redwood City, CA). Age, gender, karyotype and 
phenotypic features of the analyzed samples are provided in Table 1. 
ANOVA was used to identify all genes that differed at level of p <0.01 and 
p <0.05 and these were further filtered for data quality and for differences in 
hybridization signals of 1.2-fold above the experiment mean. Corrections for 
multiple tests comparisons were been also applied. Finally, the Gene Tree 
function was used to group the differentially expressed genes into over-
expressed and under-expressed. 
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Table 1. Characteristics of the samples analysed in the study 
 
Samples Karyotype Age (years) Phenotype 
Trisomy 21 47, XX +21 5 MR, CHD, HT 
 47, XY +21 6 MR, cataract 
 47, XX +21 4 MR, CHD 
 47, XY +21 5 MR, CHD, HT 
 47, XX +21 4 MR, R-URTI 
 47, XY +21 6 MR, HT 
Control 46, XX 5 normal 
 46, XY 6 normal 
 46, XX 4 normal 
 46, XY 3 normal 
 46, XY 5 normal 
 46, XX 6 normal 
 
MR: mental retardation; CHD: congenital heart defect; HT: hypothyroidism; R-URTI: 
recurrent upper- respiratory tract infections. 
 
 
7.1 Deregulation of functional classes and pathway perturbation 
 
For the the genome-wide expression profiles data analysis was performed 
using a p-value cut-off of 0.01 and a list of 406 differentially expressed 
transcripts, throughout the genome, was generated, corresponding to 83% 
down-regulated (n=335 ) and 17% up-regulated (n=71). 
By using DAVIDBionfomatics, all differentially expressed genes were 
categorized according to GO classification based on their hypothetical 
biological processes and molecular functions. This analysis, performed by 
submitting the two lists of down and up-regulated genes separately, revealed 
that down regulated categories were mostly associated to: ubiquitin 
metabolism; cell signalling, with a particular enrichment for NF-kappaB 
cascade; cell cycle; protein localization and regulation of gene expression 
(Table 2). 
Among up-regulated categories the most enriched resulted: developmental 
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processes and transport and localization with a strong enrichment for calcium 
ion transport (Table 3) 
Pathway analysis, performed by submitting the list of all 406 deregulated 
genes, identified ubiquitin mediated proteolysis as the pathway mostly 
influenced by trisomy 21 (p=2.9 E-5; fold enrichment= 4.8).  
 
Table 2. Enriched GO categories of down-regulated gene (FDR 0.01), sorted by p-
value 
Categories n. of genes 
% of genes 
in list 
category 
p-value 
fold 
enrichmen
t 
 
Ubiquitin metabolism 
    
ubiquitin-dependent protein 
catabolic process 
16 5.4 5.2E-6 4.3 
modification-dependent 
protein catabolic process 
25 8.5 1.4E-5 2.7 
proteolysis involved in 
cellular protein catabolic 
process 
25 8.5 2.9E-5 2.6 
proteolysis 29 9.8 0,0093 1.6 
proteasomal ubiquitin-
dependent protein catabolic 
process 
6 2.0 0,025 3.6 
ligase activity 17 5.8 0,001 2.6 
ubiquitin-protein ligase 
activity 
8 2.7 0,013 3.2 
 
Cell signalling 
    
positive regulation of I-
kappaB kinase/NF-kappaB 
cascade 
9 3.1 0,00021 5.5 
positive regulation of 
protein kinase cascade 
10 3.4 0,0024 3.5 
positive regulation of signal 
transduction 
12 4.1 0,01 2.4 
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Cell cycle 
    
     
mitotic cell cycle 14 4.7 0,0084 2.3 
cell cycle phase 15 5.1 0,0086 2.2 
M phase of mitotic cell cycle 10 3.4 0,013 2.7 
mitosis 9 3.1 0,031 2.4 
nuclear division 9 3.1 0,031 2.4 
interphase 6 2.0 0,033 3.3 
     
     
 
Protein localization 
    
      
establishment of protein 
localization 
25 8.5 0,0017 2.0 
     
 
Regulation of gene expression 
 
    
gene expression 62 21.0 0,022 1.3 
mRNA processing 12 4.1 0,023 2.2 
RNA splicing  11 3.7 0.024 2.3 
     
 
Vescicle related 
    
     
ER to Golgi vesicle-mediated 
transport 
4 1.4 0,033 5.6 
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Table 3. Enriched GO categories of the up-regulated gene (FDR 0.01), sorted by p-
value 
 
     
Categories  n. of 
genes 
% of genes 
in list 
category 
p-value fold 
enrichment 
     
Development     
     
cellular developmental 
process 
14 23.3 0,002 2.5 
anatomical structure 
development 
17 28.3 0,004 2.0 
cell differentiation 13 21.7 0,005 2.4 
system development 16 26.7 0,005 2.1 
multicellular organismal 
development 
17 28.3 0,015 1.8 
organ development 12 20.0 0,021 2.1 
     
 
Transport and localization 
    
     
calcium ion transport 5 8.3 0,0010 10.6 
transmembrane transport 7 11.7 0,01 3.7 
metal ion transport 6 10.0 0,016 3.9 
localization 17 28.3 0,022 1.7 
cation transport 6 10.0 0,032 3.3 
transport 15 25.0 0,034 1.7 
ion transport 7 11.7  0,035  2.8 
establishment of 
localization 
15  25.0  0,037 1.7 
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7.2 Chromosome 21 expression profiles 
Of the 168 chromosome 21 transcripts with FC ≥|1.2|, 86 corresponding to 69 
known genes resulted differentially expressed in DS vs controls 
lymphoblasts, with FC ranging from 1.20 to 2.57 and a mean DS/control ratio 
of 1.36 ± 0.2, suggesting that a substantial number of triplicated genes 
escapes the gene-dosage rule, and underscoring the presence of complex 
mechanisms of regulation of gene expression. 
To identify functional categories associated to DS, the list of the trisomic 
deregulated genes was submitted to a GO analysis. Results indicated 
regulation of ATPase activity coupled to transmembrane movement of 
substances and oxidative phosphorilation as the major enriched categories 
(Table 4). 
The analysis from three different databases (GenMapp, BioCarta and KEGG), 
showed Alzheimer’s, Parkinson’s and Huntington’s disease as the most 
deregulated biological pathways (Table 5). 
 
 
Table 4. Enriched GO categories of HSA21 up-regulated genes  
 
Term 
n. 
of genes 
Genes % P-Value 
Fold 
Enrichment 
ATPase activity, coupled 
to trans membrane 
movement of substances 
4 
ATP5O, 
ATP5J, 
ABCC13, 
ABCG1 
6.2 0.005 11.3 
Cofactor metabolic 
process 
4 
SOD1, 
FTCD, 
PDXK, 
CRYZL1 
6.2 0.029 5.8 
Regulation of cholesterol 
biosynthetic process 
 
2 
ABCG1, 
SOD1 
3.1 0.031 62.2 
Oxidative 
phosphorylation 
3 
ATP5O, 
ATP5J, 
NDUFV3 
4.7 0.04 9.2 
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Table 5. Enriched pathways of HSA21 up-regulated genes  
 
Term 
n. 
of genes 
Genes % P-Value 
Fold 
Enrichment 
Parkinson's disease 
 
4 
ATP5O, 
ATP5J, 
NDUFV3, 
UBC6/7 
6.2 0.010 8.3 
Alzheimer's disease 4 
ATP5O, 
ATP5J, 
NDUFV3, 
BACE 
6.2 0.023 6.1 
Huntington's disease 4 
ATP5O, 
ATP5J, 
NDUFV3, 
SOD1 
6.2 0.030 5.5 
 
 
 
8. Aims of the thesis 
 
The aims of the present thesis were to expand the knowledge on the 
molecular bases of DS and to provide new tools that could be useful for the 
development of innovative therapeutic approaches.  
For this purpose, different objectives and different strategies have been 
applied. 
The previous genome-wide analysis, which allowed us to compare DS and 
euploid lymphoblasts expression profiles, identified ubiquitin mediated 
proteolysis as the pathway most influenced by trisomy 21, whereas ubiquitin 
metabolism and regulation of NFkappaB cascade resulted to be two of the 
most significant down regulated GO categories.  
On the basis of these results and of the data present in the literature, the 
objectives developed in the present thesis were: 
- Functional analysis of the ubiquitin-proteasome system (UPS), both to 
validate microarray data and to investigate its involvement in DS 
phenotype. 
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- Functional analysis of the NFkappaB pathway, both to validate 
microarray results and to study model proteins regulated by 
ubiquitination in association to DS.  
- Analysis of the DYRK1A/DSCR1/NFAT pathway, suggested as a 
candidate pathway with a role in mice models of trisomy 21 (Arron et 
al., 2006), but still not well investigated in human DS samples. 
Finally, since MCPH1, a causative gene of primary microcephaly in 
consanguineous Pakistani families (Roberts et al., 2002; Woods et al., 2005), 
was found significantly down-regulated in our population of subjects with 
Down syndrome, in whom syndromic microcephaly has been described, we 
performed a sequencing analysis of the entire gene to identify the presence of 
possible alterations also in a population of unrelated patients with primary 
microcephaly from different ethnic groups. 
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INTRODUCTION 
 
1. Ubiquitin-proteasome system 
The ubiquitin proteasome system (UPS) is the major proteolytic pathway 
used by eukaryotic cells to metabolize proteins (Ciechanover, 2005).  
The substrate is first marked for degradation by covalent linkage to ubiquitin, 
a small 8.5 kDa protein. After the first ubiquitin is attached to the protein to 
be degraded, further ubiquitin molecules (4 to 7) are bound to form a 
polyubiquitin chain through the action of three different enzymes termed E1, 
E2, and E3, in ATP dependent manner. The polyubiquitinated protein is then 
targeted to a multi-subunit protease termed proteasome 26S which has a 20S 
catalytic core, that possesses three different proteolitic activities: 
chimotrypsin-like; trypsin-like and caspase-like (Rechsteiner et al., 2005; 
Kisselev et al., 2002); and two 19S regulatory caps (Baumeister et al., 1998; 
Wolf et al., 2004).  
At the proteasome, the polyubiquitinated substrate is degraded to small 
peptides and amino acids, while the polyubiquitin chain is disassembled to 
ubiquitin monomers that are released for future use (Glickman et al., 2002; 
Rajkumar et al., 2005; Nussbaum et al., 1998) (Fig. 1) 
UPS is known to metabolize not only misfolded, oxidized and damaged 
proteins, but also proteins involved in many cellular processes such as 
cyclins, transcriptional activators and their inhibitors, and components of 
signal transduction pathways. Ultimately, a link between protein synthesis 
and degradation by UPS has been proposed (Ding et al., 2006). 
Intracellular protein degradation is relevant for most cellular and 
physiological functions including: apoptosis, cell cycle progression, 
differentiation, stress response, DNA repair and antigen presentation in the 
immune response. 
The pathological states associated with the ubiquitin system can be classified 
into two groups: those that result from loss of function, such as mutation in a 
ubiquitinating enzyme, that result in stabilization of certain proteins; and 
those that result from gain of function and abnormal or accelerated 
degradation of the protein target. 
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Fig. 1 Ubiquitination of proteasomal substrate proteins is performed by a complex system 
consisting of ubiquitin activating (E1) enzymes, ubiquitin-conjugating (E2) enzymes and 
substrate recognition proteins (E3 enzymes). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
By http://ocw.mit.edu/courses/biology/7-340-ubiquitination-the-proteasome-and-human-disease-fall-2004/ 
 
 
Alterations in ubiquitination and deubiquitination reactions have been directly 
implicated in the etiology of many malignancies through the stabilization of 
oncoproteins or destabilization of tumor suppressor genes. Furthermore, 
accumulation of ubiquitin conjugates and/or inclusion bodies associated with 
ubiquitin, proteasome, and certain disease-characteristic proteins have been 
reported in a broad array of chronic neurodegenerative diseases, such as the 
neurofibrillary tangles of Alzheimer’s disease (AD), brain stem Lewy bodies 
(LBs) in Parkinson’s disease (PD) and intracellular bodies in Huntington’s 
disease (reviewed by van Tijn et al., 2008; Glickman MH et al., 2002). 
Finally, the ubiquitin system is also involved in immune and inflammatory 
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response: it degrades, in a nondiscriminatory manner, both intracellular “self 
” as well as foreign “non-self” proteins such as viral proteins. Peptides from 
both populations are presented to CTLs, but those that are derived from self 
proteins do not elicit a T-cell response. It is easy to imagine that aberrations 
in processing of these proteins may lead to autoimmune diseases. 
 
 
1.1 UPS activity, oxidative stress (OS) and mitochondrial function  
 
An imbalance of the cell redox activity is known to be a feature of DS (Zana 
et al., 2007; Galletti et al., 2007; Carratelli et al., 2001; Zitnanova et al., 2006; 
Pastore et al., 2001; Michova et al., 2007) and was proposed as a key player 
in the pathogenesis since the accumulation of proteins modified by reactive 
oxygen species (ROS) may have a crucial role in neurodegeneration, 
premature aging, autoimmune diseases and cataratta also present in DS. 
However, the causes of chronic oxidative stress observed in DS subjects are 
not yet known and there is no definitive consensus on whether OS is mediated 
by increased oxidation, decreased antioxidant levels, or insufficient clearance 
of oxidized proteins.  
Several studies reported that oxidized proteins are selectively cleared by the 
ubiquitin-proteasome system (UPS) upon OS (Poppek et al., 2006; Breusing 
et al., 2008) and that there is a decline of the proteasomal activity after sub-
lethal OS, followed by a functional recovery in the after-stress period 
(Reinheckel et al., 1998).  
Furthermore, it was reported that as the proteasome is made by proteins, it 
may be itself damaged by oxidative stress, in particular the 19S regulatory 
particle (Prendmore et. al., 2010; Reinheckel et al., 2000). Other components 
of the UPS are regulated by OS as well, with a transient decrease of Ub-
conjugates during stress, followed by increase in the Ub-conjugates during 
recovery (Shang et al., 1997). 
Since mitochondria are the main source of ROS, UPS activity is tightly 
connected with mitochondrial function. A close relationship between 
mitochondrial abnormalities and oxidative damage have been described in DS 
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brains and fibroblasts (Busciglio et al., 2002 ; Raha et al., 2000) and gene 
expression variations of oxidative phosphorylation units, increased levels of 
the Krebs cycle enzymes and impaired mtDNA repair systems (Kim et al., 
2000; Kim et al., 2001; Lee et al., 2003; Bajo et al., 2002; Druzhyna et al., 
1998) were described in human DS cells.  
Furthermore, also some mitochondrial proteins are degraded by UPS that, 
along with autophagy, is involved also in the clearance of damaged 
mitochondria from the cell (Carlucci et. al., 2008; Carrard et al., 2002). At 
least 4 E3 ligases are localized to the mitochondria. One of these, MULAN, is 
also an activator of NF-kappaB, thus providing a mitochondria-to-nucleus 
signalling (Li et al., 2008). Deubiquitinating enzymes (USP30) present in the 
mitochondrial outer membrane regulate mitochondrial morphology as well 
(Nakamura et al., 2008). Finally, a dinucleotide deletion in Ub-B mRNA 
leads to formation of polyubiquitin (UbB)+1 and causes mitochondrial stress 
and neuronal degeneration in primary neurons (Tan et al., 2007). 
 
 
 
OBJECTIVE 
 
A preliminary genome-wide expression analysis performed by our group, 
revealed that ubiquitn mediated proteolysis is the pathway mostly influenced 
by trisomy 21 in lymphoblastoid cell lines, in particular among the down-
regulated GO categories.  
UPS is mainly involved in the degradation of oxidized or damaged proteins 
and chronic oxidative stress is a feature of DS. 
Hence, since there has been increasing interest in the ubiquitin-proteasome 
system (UPS) because of its possible role in neurodegenerative diseases, 
autoimmune disorders and cancer, functional analyses were performed to 
investigate its involvement in the DS phenotype. 
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MATERIALS AND METHODS 
 
Cell culture and treatment 
Peripheral blood samples were collected, after informed consent, from control 
and karyotipically confirmed full trisomy 21 children. All subjects were 
recruited at the Department of Pediatrics, Federico II University of Naples, 
the regional referral center for DS.  
Lymphocytes were isolated by using Ficoll-Hypaque (Gibco) and then 
immortalized by Epstein-Bar Virus (EBV) to generate lymphoblastoid cell 
lines (LCLs). 
Cells were grown in RPMI-1640 (Cambrex) supplemented with 20% fetal 
bovine serum, 5000U/ml penicillin-streptomycin, 2 Mm glutamine (Gibco) 
and 0.16 mg/ml gentamicin, at 37°C. 
Oxidative stress was induced with 0.1 mM H2O2 for 30 minutes and the 
recovery was evaluated 1, 2 and 4 hours after resuspention in fresh RPMI. 
The proteasome blocking was induced with 50μM MG-132 (Calbiochem) for 
6 hours at 37°C for western blot experiments, and 100 μM MG-132 for 2 
hours for the proteasome activity assay.  
 
Protein extraction 
Total protein extraction was carried out lysing the cells with the Tropix lysis 
solution (Applied Biosystems) supplemented with 0.1 M DTT, protease 
inhibitor cocktail 1X (Sigma), 50 M MG-132 (Calbiochem) and 5 mM 
Manganese according to Mimnaugh and Neckers protocol (Mimnaugh and 
Neckers, 2002) 
 
Western blot analysis 
Protein extracts (20-40 µgr) were separated by 10% SDS-PAGE and then 
transferred on PVDF membrane (Millipore). Membranes were then blocked 
for 1 hour in milk 5% - PBS 1X-0.1% Tween-20 (T-PBS) and then incubated 
overnight with diluitions of specific primary antibodie anti-ubiquitina (P4D1) 
(CellSignalling). 
Anti-mouse IgG horseradish peroxidase conjugated (GE-Healthcare) was 
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used as secondary antibody and the specific bands were visualized by ECL 
reaction (GE-Healthcare).  
 
Luminescent proteasome assay 
To individually measure the chymotrypsin-like, trypsin-like and caspase-like 
protease activity associated with the proteasome complex in cultured cells we 
used the Proteasome-Glo™ 3 substrates Cell-Based Assay (Promega). 
Reagents from this kit contain three specific luminogenic proteasome 
substrates in a buffer optimized for cell permeabilization, proteasome activity 
and luciferase activity. For the Chymotrypsin-Like Assay, there is the Suc-
LLVY-Glo™ Substrate; for the Trypsin-Like Assay the Z-LRR-Glo™ 
Substrate; and for the Caspase-Like Assay there is the Z-nLPnLD-Glo™ 
Substrate. 
Each sample was performed in duplicate and in two separate experiments and 
for each of them were considered : 
 
• Blank: Proteasome-Glo™ Cell-Based Reagent + culture medium (without 
cells) and vehicle control used (DMSO), to measure the background 
luminescence 
• Test : Proteasome-Glo™ Cell-Based Reagent + culture medium containing 
cells and vehicle control (DMSO) 
• Treatment-Test: Proteasome-Glo™ Cell-Based Reagent + culture medium 
containing cells with treatment compound (H2O2) and vehicle control 
(DMSO) 
• Inhibitor Control: Proteasome-Glo™ Cell-Based Reagent + culture medium 
containing cells with a specific proteasome inhibitor (MG-132 in DMSO ), to 
identify nonspecific protease activity not related to the proteasome. 
 
Lymphoblastoid cell lines, in concentration of 20,000/well in a 96-well plate, 
were incubated at 37°C overnight and then treated with 100 μM MG-132 for 
2 hours and 0.1 mM H2O2 for 30 minutes, before adding the Proteasome-
Glo™ Cell-Based Reagents. The luminescence was read after 15 minutes in a 
plate-reading luminometer (TECAN) 
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Statistical Analysis  
The data were reported as the means ± S.E. and the statistical significance of 
differences between means was assessed by using the two-tail unpaired 
Student's t test. The differences between the means were accepted as 
statistically significant at the 95% level (p = 0.05). 
 
 
 
RESULTS 
 
The ubiquitn-proteasome system was investigated in DS lymphoblastoid cell 
lines by Western blot analysis and proteasome activity assay. 
Western blot analysis, performed on total proteins extracted before and after 
proteasome blocking with MG132, showed that in DS there is a significant 
reduction of ubiquitinated protein levels before treatment and a surprising 
increase of their accumulation following MG132 treatment (Fig. 2, 3). 
The same experiments, performed before and after oxidative stress induction 
with H2O2, showed that in DS there is an increase of the accumulation of the 
ubiquitinated proteins also under stress conditions and that there is a slower 
recovery of their basal levels compared to controls. (Fig 4, 5) 
The subsequent proteasome activity assay, performed on cells before and 
after H2O2 induction, revealed a significative increase in the trypsin-like and 
in the chymotripsin-like activitity (p≤0.01) in DS subjects, both in basal and 
stress conditions, while no difference was observed for the caspase-like 
activity (Fig. 6) 
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Fig. 2 Western blot analysis of total protein levels and their ubiquitination state in basal 
condition and following proteasome blocking (+ 50 µM MG132 for six hours).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 Densitometry of the ubiquitinated protein levels showed by Western blot analysis in 
basal condition and following proteasome blocking 
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Fig. 4 Western blot analysis of the ubiquitinated protein levels in basal condition and after 
oxidative stress (0,1 mM H2O2 for 30 minutes) and after 1, 2 and 4 hour of recovery 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5 Densitometry of the ubiquitinated protein levels observed after oxidative stress 
conditions and recovery. 
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Fig. 6 Analysis of the three proteasome activities in basal conditions and after treatment with 
H2O2 (0,1 mM for 30 minutes). The average of the sample activities of pool of DS subjects 
versus controls (n=3) was evaluated in duplicate and repeat two times. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION  
 
The 26S proteasome is the enzymatic core engine of the ubiquitin dependent 
proteolytic system (UPS), the major eukaryotic pathway for regulated protein 
degradation. The UPS plays a pivotal role in cellular protein turnover, protein 
quality control, antigen processing, signal transduction, cell cycle regulation, 
cell differentiation and apoptosis. Hence, aberrations in this system underlie, 
directly or indirectly, the pathogenesis of several diseases including some 
observed in DS such as neurodegenerative diseases (Alzheimer's, Parkinson's 
and Huntington’s disease), autoimmune disorders and cancer. 
Genome-wide expression analysis and bioinformatic tools revealed that 
PROTEASOME ACTIVITY ASSAY  
* 
* 
* 
* 
* 
p<0.05 * 
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ubiquitin mediated proteolysis is the pathway mostly influenced by trisomy 
21 in lymphoblastoid cell lines and in particular among the down-regulated 
GO categories. 
In the present study, functional analyses of the UPS revealed that there is a 
reduction of the ubiquitinated protein levels and a consistent increase in two 
of the three proteasome activities in DS cell lines in basal conditions. 
Furthermore, it was observed an increase in the accumulation of ubiquitinated 
proteins in DS compared to controls under oxidative stress conditions, and a 
significant increase of the same proteasome activities observed in basal 
conditions.  
Taken togheter, this results suggested that in human DS lymphoblastoid cell 
lines there is a defective protein degradation system that could result from a 
primary dysfunction of UPS and from an excess of damaged proteins, such as 
oxidated proteins, that could cause an UPS overload 
To date, except to a recent expression study in cultured DS trophoblasts that 
showed a down-regulation of the Ub-mediated proteolysis (Rozovski et al., 
2007), no data are available on the function of the UPS in DS. Only one study 
on the cerebellum of a DS mouse model reported a reduction of the 
proteasome chymotrypsin-like activity and an increase in ubiquitinated 
proteins (Necchi et al., 2011) in contrast with the present findings.  
Furthermore, it was reported that a decline of the proteasomal activity occurs 
after sub-lethal OS, followed by a functional recovery in the after-stress 
period (Reinheckel et al., 1998). Increased accumulation of highly oxidized 
proteins has been attributed to decreased proteasome function during aging 
(Das et al., 2007; Sitte et al., 2000; Stadtman et al., 2001), but UPS 
modifications induced by stress response in DS are still unexplored. Only 
Engidawork and co-workers (2001) showed a significant overexpression of 
the proteasome zeta chain and of the T isopeptidase deubiquitinating enzyme 
in DS fetal brain compared to controls, probably due to ROS accumulation 
(Busciglio and Yanker, 1995). 
However, since most studies were performed on DS brains, our findings, 
assessing an impairments of the UPS in human DS lymphoblastoid cell lines, 
offer new perspective to study this system in association to DS phenotipic 
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features not only of neurodegenerative origin.  
Further studies are needed to investigate if also the activities of some of the 
enzymes involved in the ubiquitin system degradation (E1, E2 and E3 and 
deubiquitinating enzymes) are affected. 
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Down-regulation of the NF-KappaB pathway in  
Down syndrome 
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INTRODUCTION  
 
NF-κB is a dimeric transcription factor formed by members of a highly 
conserved family of proteins that share an ∼300-amino-acid region termed the 
Rel Homology Domain (RHD) (Karin and Lin 2002) through which they can 
form homodimers and heterodimers that bind to 9-10 base pair DNA sites, 
known as kB sites, in the promoters and enhancer regions of genes, thereby 
modulating gene expression. 
In mammals, the NFkB family is composed of five related transcription 
factors: p50, p52, RelA (p65), c-Rel and RelB (Moynagh 2005; Hoffmann et 
al., 2006). 
RelA, c-Rel and RelB contain C-terminal transcriptional activation domains 
(TADs), which enable them to activate target gene expression. In contrast, 
p50 and p52 do not contain C-terminal TADs; therefore, they are bound to a 
protein RelA, c-Rel or RelB acting as transcriptional co-activators. In 
particular, the p50/p65 heterodimer is the most abundant form in eukaryotic 
cells.  
NF-Kappa B is activated by two-step proteolytic mechanism: a primary 
processing of the precursor protein (p100 and p105 to yield the active subunit 
p52 and p50 rispectively) and signal induced phosphorylation and subsequent 
degradation of its inhibitor IkB . 
Inhibitory IκB proteins sequestrate NFkB dimers into the cytoplasm and 
include: Ik-Balfa (IKBA), Ik-Bbeta, Ik-Bepsilon (Baeuerle and Baltimore 
1988).  
In the canonical signaling pathway, the binding of ligand to a cell surface 
receptor, such as a member of the the Toll-like receptor superfamily, leads to 
activation of the multimeric IκB Kinase (IKK) that results in the 
phosphorylation of IκB, followed by its ubiquitination and degradation 
(Henkel et al., 1993; Chen et al., 1995), allowing the translocation of NF-kB 
dimers, composed by RelA, c-Rel o RelB and p50, into the nucleus. (Karin 
1999; Tergaonkar 2006; Gilmore 2006; Scheidereit 2006). (Fig. 1) 
More recently, additional mechanisms for transcriptional regulation have 
been recognized, including post-translational modifications of NF-κB 
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subunits such as phosphorylation (Zhong et al., 1998; Sakurai et al., 1999), 
acetylation (Chen et al., 2001; Kiernan et al., 2003), prolyl-isomerization 
(Ryo et al., 2003), and ubiquitination (Saccani et al., 2004; Maine et al., 2007; 
Tanaka et al., 2007). 
 
Fig. 1 The binding of ligand to a receptor leads to the recruitment and activation of an IKK 
complex comprising IKK alpha and/or IKK beta catalytic subunits and two molecules of 
NEMO. The IKK complex then phosphorylates IkB leading to degradation by the 
proteasome. NFkB then translocates to the nucleus to activate target genes regulated by kB 
sites. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
By Hooper C. “Overview of NFkB signaling” 
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Activation of the factor stimulates the transcription of many cytokines, 
adhesion molecules, inflammatory response, stress proteins, and immune 
system receptors; hence, deregulations of this pathway have been related to a 
wide array of immune and inflammatory disorders , but also to apoptosis and 
delay of cell growth. 
 
 
 
1. NF-kappaB and NFAT pathway in Down syndrome  
 
Down syndrome, caused by the presence of three copies of chromosome 21, 
is characterized by many typical phenotypes, such as immune deficiency, 
characteristic facial features, mental retardation, congenital heart disease, and 
early onset of Alzheimer disease. Overexpression of a number of chr21 genes 
is thought to be responsible, directly or indirectly, for some of these clinical 
features. 
Among them, DSCR1 (Down syndrome candidate region 1) gene, located in 
the Down syndrome critical region of chromosome 21 (Fuentes et al., 1997; 
Pfister et al., 2002) appears be linked to mental retardation, inflammation, 
angiogenesis, and cardiac development (Harris et al., 2005; Hesser et al., 
2004; Ryeom et al., 2003; Yao et al., 2004). 
DSCR1 is highly expressed in the brain, heart, and skeletal muscles of DS 
fetuses (Fuentes et al., 1995) and it is known to interact physically and 
functionally with Ca2+/calmodulin-dependent protein phosphatase 2B (also 
known as calcineurin A), suppressing its signaling (Fuentes et al., 2000; 
Rotherme et al., 2000). Recently, Arron and co-workers (2006) found that, 
together with DYRK1A, another critical chr 21 gene, DSCR acts to control 
the nuclear localization of the NFAT family of transcription factors, key 
regulators of vertebrate development, and associated to cardiovascular, 
neurological, skeletal and immune phenotype strikingly similar to DS. 
In immortalized hippocampal cells as well as in primary cortical neurons, it 
was found that NF-kappaB-inducing kinase (NIK) selectively binds to and 
phosphorylates the C-terminal region of DSCR1 increasing its protein 
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stability and blocking its proteasomal degradation leading to an increase in 
soluble and insoluble DSCR1 levels with cytotoxic effects (Lee et al., 2007). 
Other findings showed that DSCR1 overexpression decreases the basal 
turnover rate of IκBα and consequently attenuates the steady-state and 
stimulus-induced transcriptional activity of NF-κB in human glioblastoma 
cells, inhibiting the induction of genes involved in the inflammatory response 
(Kim et al., 2006) 
These evidences demonstrated a link between the NF-kappaB and the NFAT 
pathway and suggest new hypotheses for the involvemet of these two 
pathways in the DS pathogenesis. 
 
 
 
OBJECTIVE 
 
GO analysis of our previous microarray study from DS lymphoblastoid cell 
lines revealed a significant down-regulation of the NF-kappaB cascade and of 
ubiquitin mediated proteolysis. Since NF-kappaB activity is regulated by 
ubiquitin dependent degradation of its inhibitor and published evidences (Lee 
et al., 2007). Kim et al. (2006) linked the NF-kappaB to the NFAT pathway, a 
recent candidate player in the DS phenotype, functional analyses were 
performed to investigate alterations of this pathway and its association to DS.  
 
 
 
MATERIALS AND METHODS 
 
Samples  
Lymphoblastoid cell lines from karyotipically confirmed full trisomy 21 
children and controls were obtained, after informed consent, collecting 
peripheral blood samples, isolating lymphocytes by using Ficoll-Hypaque 
(Gibco), and then immortalizing them by Epstein-Bar Virus (EBV). All 
subjects were recruited at the Department of Pediatrics, Federico II University 
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of Naples, the regional referral center for DS.  
Cells were grown in RPMI-1640 (Cambrex) supplemented with 20% fetal 
bovine serum, 5000U/ml penicillin-streptomycin, 2 Mm glutamine (Gibco) 
and 0.16 mg/ml gentamicin, at 37°C. 
 
Protein extraction 
Total protein extraction was obtained by lysing the cells with the Tropix lysis 
solution (Applied Biosystems) supplemented with 0.1 M DTT and in 
presence of protease inhibitor cocktail 1X ( Sigma). Cytoplasmic and nuclear 
fractions from cells were obtained by using celLytic NucLEAR Extraction kit 
(Sigma). Briefly, cells were lysed in isotonic buffer with 0.1 M DTT and 
protease inhibitor cocktail 1X and incubated on ice for 15 minutes. IGEPAL 
CA-630 solution to a final concentration of 0.6% was added to the swollen 
cells, and cytoplasmic fraction was obtained by centrifugation at 10000 X g 
for 30 seconds at 4°C. The nuclei pellets were resuspended in extraction 
buffer with 0.1 M DTT in presence of protease inhibitor cocktail 1X and 
vortexed for 30 minutes at 4°C. The pellet fraction was collected by 
centrifugation at 20000 X g for 5 minutes at 4°C.  
 
Western blot analysis 
Protein extracts (20-40 µgr) were separated by 8-10% SDS-PAGE and then 
transferred on PVDF membrane (Millipore). Membranes were then blocked 
for 1 hour in milk 5% - PBS 1X-0.1% Tween-20 (T-PBS) and then incubated 
overnight with dilutions of specific primary antibodies: anti-NF-kB p65, anti-
p105/p50, anti-IkBα (L35A5) and anti-pIKBA (CellSignalling).  
Antibodies IgG anti-mouse and anti-rabbit, horseradish peroxidase 
conjugated (GE-Healthcare), were used as secondary antibody and the 
specific bands were visualized by ECL reaction on high performance 
chemiluminescent film (GE-Healthcare). 
 
Luciferase assay 
Lymphoblastoid cell lines from DS subjects and controls were plated in 24-
well plates at density of 5x10
5
 cells/well. Transfection of the different 
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plasmids, the specific pNF-KB-Luc (Path Detect NF-KB Cis-Reporting 
System, Stratagene) and pCMV β expressing the β-galactosidase (Clontech), 
was performed 24 hours later with Turbofect Transfection Reagent 
(Fermentas), according to the manufacturer’s instructions. Cells were 
harvested and processed after 48 hour. Luciferase and β-galactosidase 
expression was measured with Dual Light Luciferase Assay Kit (Applied 
Biosystem). 
 
EMSA 
For the EMSA the Gel Shift Assay (Promega) was used. Nuclear extracts (20 
µg) were incubated for 30 minutes at room temperature with a radioactive 
labeled ([γ-32P]dATP) oligonucleotide probe containing the specific 
recognition sequence for NF-kB (AGT TGA GGG GAC TTT CCC AGG C), 
a Binding Buffer 5x and Poly-dIdC. After binding, the samples were 
separated on a 6% non-denaturating PAGE gel for 2 hours and bands were 
detected by autoradiography after being dried and stored at -80
0
 overnight. 
To check if the observed shifted bands were specific for NF-kB, protein 
extracts were incubated with an additional nonlabeled ("cold") 
oligonucleotide for competition test. 
 
Statistical Analysis  
The data were reported as the means ± S.E. and the statistical significance of 
differences between means was assessed by using the two-tail unpaired 
Student's t test. The differences between the means were accepted as 
statistically significant at the 95% level (p = 0.05). 
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RESULTS 
 
In the present study, the NF-kappaB pathway was investigated in DS and 
control samples by Western blot, EMSA and luciferase assays. 
Western blot experiments, performed on cytosolic and nuclear fractions, 
showed that in DS there is a significant increase of IKBα in the cytosolic 
fractions in both dephosphorilated and phosphorilated forms (Fig. 2), while 
there is a significant reduction of the NF-kappaB p65 subunit levels in the 
nuclear fractions (Fig. 3). No difference was observed for the cytosolic p65 
levels and for the NF-kappaB p50 subunit levels, both in the nuclear and in 
the cytosolic fractions of DS compared to controls. 
To evaluate the effect of the observed alterations, we performed EMSA 
experiments that showed a reduction of the NF-kappaB binding activity of the 
DS nuclear subunits, and luciferase assays that assessed a significant 
reduction also of the NF-kappaB transcriptional activity in DS cell lines 
compared to controls (Fig. 4, 5). 
Finally, immunoprecipitations of IkBa on cytosolic fractions and subsequent 
Western blot experiments with specific anti-ubiquitin antibody, showed a 
reduction of the ubiquitinated levels of this inhibitor, supporting the 
hypothesis of an impaired degradation that could be cause of the previous 
observed cytosolic accumulation. (Fig. 6). 
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Fig. 2 Western blot of IKappaBα and p-IKappaBα cytosolic levels 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 Western blot of NFkappaB p65 subunit nuclear levels  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
* 
* 
Cytosolic  
IKappaBα and p-IKappaBα 
  
Nuclear  
NFkappaB p65 
pIKappaBα 
  
IKappaBα 
p<0.05 * 
* p<0.05 
 - 73 - 
Fig. 4 EMSA of NF- B DNA-binding activity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5 Luciferase expression under the control of NFkappaB transcriptional activity. 
Histograms show the relative light units (RLU) of pool of DS subjects versus controls (n=3). 
The average of the sample activity observed was normalized on the average of the b-
galactosidase activity. Experiments were done in duplicate and repeated two times 
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Fig. 6 Ubiquitination of IKBa. A) Cytoplasmic extracts were immunoprecipitated for IKBα 
and then analyzed by Western blot using an antibody against ubiquitin. IgG H ang IgG L 
indicates immunoglobulin heavy and light chains in the immunoprecipitates that cross-reacts 
with the secondary antibody. B ) Relative densitometry of ubiquitination levels of NFkappaB 
inhibitor. Integrated density was evaluated by normalizing ubiquitin density on that of IKBα 
 
 
 
A)         B) 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
NFkappaB is a dimeric transcription factor activated by the ubiquitin system 
via a two-step proteolytic mechanism: processing of precursor proteins and 
signal induced phosphorylation and subsequent degradation of the IKB 
inhibitors. 
GO analysis of differentially expressed genes resulted from our previous 
microarray data revealed both, NFkappaB cascade and ubiquitin metabolism, 
among the down-regulated categories.  
To confirm that regulation through this transcription factor is affected in 
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Down syndrome lymphoblastoid cell lines, functional studies were 
performed.  
Our results revealed a significant increase of IKBα, both phosphorylated and 
not phosphorylated, in the cytosolic fractions of DS subjects and a reduction 
of the NF-kappaB p65 subunit levels in DS nuclear fractions. In agreement 
with these results, a significant reduction of the NF-kappaB transcriptional 
activity was showed in DS cell lines. 
Finally, the ubiquitinated levels of IKBα were found to be reduced in DS 
compared to control subjects. 
These results confirmed that in DS lymphoblastoid cell lines there is a down-
regulation of the NF-kappaB cascade and suggested that this alteration should 
be also a consequence of the previously observed ubiquitin proteasome 
system deregulation. 
Since recent evidences demonstrated a link between NF-kappaB and NFAT 
pathway that was recently proposed as one of the candidate pathway for DS 
phenotype, and that NF-kappaB itself is connected to a wide array of features 
also seen in DS such as immune and inflammatory disorders, apoptosis and 
cell growth delay, our findings suggested that this transcriptor factor might 
have a possible role in the DS pathogenesis and that further analyses should 
be carried out.  
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INTRODUCTION 
 
Down syndrome is caused by the presence of full trisomy of chromosome 21 
or of only the distal half of Hsa21, band q22. 
Therefore, it is presumed that a relatively small region of Hsa21 plays a major 
role in DS phenotypes, and the concept of a Down syndrome critical region 
(DSCR) has been proposed (Korenberg et al., 1990; 1994). DSCR was 
defined with a proximal boundary between markers D21S17 (35.1 Mb) and 
D21S55 (38.0 Mb) and a distal boundary at MX1 (41.7 Mb). This region 
spans 3.8–6.5 Mb and contains up to 25–50 genes (Delabar et al., 1993; 
Korenberg et al., 1994). Even if many studies revealed that the triplication of 
DSCR is important but not sufﬁcient for some DS phenotypes (Olson et al., 
2007; Korbel et al., 2009), expression deregulations of genes mapping on this 
region, alone or in cooperation, were suggested as responsible for some 
clinical manifestations including mental retardation, congenital heart defects, 
gastrointestinal malformations, immune and endocrine system defects, and 
early onset of dementia of the Alzheimer type. 
Recently, two chromosome 21 genes, Dyrk1A and RCAN1, both mapping on 
DSCR, have been associated to some of these phenotypes and were 
associated to Down syndrome by regulating the nuclear factor of activated T 
cells (NFAT) (Arron et al., 2006). 
Dyrk1A is a dual-specificity protein kinase that is activated by 
autophosphorylation on a tyrosine residue in the activation loop, and it 
phosphorylates serine or threonine residues in cytosolic and nuclear substrate 
proteins such as transcription factors, splicing factors, and synapse-associated 
proteins (Becker et al; 2011; Park et al.; 2009). Dyrk1A also functions as a 
priming kinase for GSK3 phosphorylation of proteins such as Tau and NFAT 
(Woods et al., 2001; Gwack et al., 2006). The protein encoded by Dyrk1A is 
considered a protein potentially responsible for mental retardation (Kentrup et 
al., 1996; Song et al., 1996; Guinera et al., 1996; Shindoh et al., 1996) and 
early onset of AD-like symptoms (Park et al.; 2009, Ryo et al., 2008; Ryo et 
al., 2007; Kimura et. al, 2007; Park et al., 2007; Ryu et al., 2010) in DS 
patients. Transgenic mice overexpressing Dyrk1A (Dyrk1A TG mice) show 
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severe hippocampal-dependent learning and memory defects (Smith et al., 
1997; Ahn et al., 2006; Altafas et al., 2001). Overexpression of Dyrk1A in 
DS brains may contribute to early onset of AD through hyperphosphorylation 
of Tau and enhancement of Aβ production, potentially due to the 
phosphorylation of APP and Presenilin 1 (Ryo et al., 2008; Ryo et al., 2007; 
Ryu et al., 2010). Finally, it plays also a critical role in neurodevelopment, 
including neuronal differentiation and synaptic plasticity (Tejedore et al., 
2011).  
DSCR1 (Down syndrome critical region 1) also termed RCAN1, is known to 
act as an endogenous regulator of Calcineurin (Caln), a ubiquitous and 
multifunctional calcium-activated serine/threonine protein phosphatase and 
its overexpression results in the inhibition of signaling pathways that are 
controlled by the nuclear factor of activated T cells (NFAT) (Davies et al., 
2011).  
DSCR1 is widely expressed in the brain, both during development and in 
adults (Porta et al., 2007), and DSCR1−/− mice showed impairments in 
spatial learning and memory (Hoeffer et al., 2007). So, this gene results as a 
candidate protein responsible for mental retardation in DS.  
DSCR1 and DYRK1A, were proposed for the first time as strong candidates 
for the DS pathogenesis when Arron and coworkers (2006) reported that they 
act synergistically to prevent nuclear occupancy of the NFATc transcription 
factors in mice models and showed that knock-out mice for some of the 
NFAT family members (NFATc1, NFATc2, NFATc3 and NFATc4), 
displayed cardiovascular, neurological, skeletal and immune phenotypes 
strikingly similar to DS.  
The nuclear factors of activated T cells (NF-ATs) are members of a family of 
transcription factors that includes five members (NFATc1-5) involved in the 
expression of cytokines and genes of the immune response. Like their distant 
relatives, the Rel family which includes NF-κB, NFATc are located in the 
cytoplasm of resting cells in a phosphorylated form and, except for NFATc5, 
are all activated by calcineurin, following Calcium signalling. Calcineurin 
induces their dephosphorylation and translocation into the nucleus, where 
they cooperate with other proteins (NFATn) to form complexes on DNA. 
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(Luo et al., 1996). (Fig. 1) 
Even if NFATc2 is more expressed in T lymphocytes (80%), the NFATc 
family is expressed in several cells and tissues, transducing calcium signals 
also in the, cardiac, muscular and nervous system.(Crabtree 1999) 
They can act with a dual function: in differentiated cells they can regulate the 
early activation of inducible genes while in some tissues can control cell 
differentiation and adaptation with a role in the regulation of chondrocytes, 
myocytes, adipocytes and keratinocytes, and in the development of cardiac 
valves and cardiac muscle cells (Horsley et al., 2002).  
 
 
 
Fig. 1. Activation of NFAT. Calcium influx leads to calcineurin-mediated NFATc 
dephosphorylation, nuclear entry, and activation of NFATc target genes. DSCR1, an inhibitor 
of calcineurin, and DYRK1A, a nuclear serine/threonine kinase, act synergistically to prevent 
NFAT nuclear export. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                     By Epstein CJ. Nature, 2006; 441:582–583. 
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OBJECTIVE 
 
Since DYRK1A and DSCR1, two genes mapping on chromosome 21 within 
the Down syndrome critical region, are associated to mental retardation and 
early onset of Alzheimer’s disease, and to the negative regulation of the the 
NFAT transcription factors leading to phenotypes similar to DS (Arron et al. 
2006), we analyzed the DYRK1A/DSCR1/NFAT pathway to evaluate the 
effect of these two trisomic genes in human DS lymphoblastoid cell lines and 
their involvement in the DS pathogenesis. 
 
 
 
MATERIALS AND METHODS 
 
Cell culture and treatment 
Lymphoblastoid cell lines (LCLs) were generated from peripheral blood 
samples, after informed consent, from controls and kariotipically confirmed 
full trisomy 21 children, recruited at the Department of Pediatrics, Federico II 
University of Naples, the regional referral center for DS. 
Lymphocytes were isolated by Ficoll-Hypaque (GIBCO), immortalized by 
Epstain-Bar virus (EBV) and grown in RPMI 1640 (Cambrex) supplemented 
with 20% fetal bovine serum (FBS), 2mM L-glutamine, 0.16 mg/ml of 
gentamicin and 5000U/ml of penicillin-streptomycin (Gibco) 
For the induction of Calcium flows, cells were incubated with 10 ng/ml PMA 
and 1 g/ml Ionomycin (Sigma) for 4 hours at 37° C. 
 
Quantitative Real-Time PCR 
Total RNA from 6 subjects with full trisomy 21 and 6 controls was obtained 
using TRIzol reagent (Gibco/BRL Life Technologies, Inc., Gaithersburg, 
MD). Quality and amount of starting RNA were confirmed using 
spectrophotometry and agarose gel electrophoresis. cDNA was synthesized 
with random hexamer primers starting from 2 g of total RNA using the High 
Capacity cDNA Archive Kit (Applied Biosystems). Real-time PCR was 
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performed using 2 g of cDNA and TaqMan Universal PCR MasterMix 2X 
on the Applied Biosystems 7300, according to the manufacturer's protocols. 
PCR reactions for each sample were performed in triplicate.  
Genes analyzed and reference genes are reported in Table 1 and 2  
 
 
Table 1. Assay used in the RT-PCR experiments 
 
GENE 
 
 
 
ASSAY ID 
 
REF SEQ 
 
EXON 
JUNCTION 
 
AMPLICONE 
LENGTH 
NFATC2 Hs00234855_m1 NM_173091.2 1 - 2 74 
NFATC1 Hs00190037_m1 NM_172390.1 2 - 3 98 
NFATC3 Hs00190046_m1 NM_173163.2 2 - 3 59 
NFATC4 Hs00232342_m1 NM_004554.3 2 - 3 99 
DYRK1A Hs00176369_m1 NM_130438.1 8 - 9 98 
DSCR1 Hs00231766_m1 NM_203418.1 3 - 4 88 
 
 
Table 2. Reference genes used in the RT-PCR experiments 
 
GENE 
 
 
 
ASSAY ID 
 
REF SEQ 
 
GIUNZIONE 
ESONI 
 
AMPLICONE 
LENGTH 
RNF111 Hs00405638_m1 NM_017610.6 6-7 98 
B2M Hs99999907_m1 NM_004048.2 2-3 75 
 
 
Protein extraction 
Total protein extraction was carried out lysing the cells with the Tropix lysis 
solution (Applied Biosystems) supplemented with 0.1 M DTT and in 
presence of protease inhibitor cocktail 1X (Sigma). Cytoplasmic and nuclear 
fractions from cells were obtained by using celLytic NucLEAR Extraction kit 
(Sigma) according to the manufacturer's instructions.  
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Western blot analysis 
Protein extracts (20-40 µgr) were separated by 8-10% SDS-PAGE and then 
transferred on PVDF membrane (Millipore). Membranes were then blocked 
for 1 hour in milk 5% - PBS 1X-0.1% Tween-20 (T-PBS) and then incubated 
overnight with diluitions of specific primary antibodies: anti-NFATc2 (4G6-
G5), anti-NFATc3, anti-NFATc4, anti-NFATc1, anti-DYRK1A (H-143) 
(SantaCruz), anti-DSCR1 (N-20) (sigma); anti- Anti-mouse and anti-rabbit 
IgG horseradish peroxidase conjugated (GE-Healthcare) was used as 
secondary antibody and the specific bands were visualized by ECL reaction 
(GE-Healthcare).Anti-tubulin and anti-H1 histone were used to 
normalization. 
 
Statistical Analysis  
The data were reported as the means ± S.E. and the statistical significance of 
differences between means was assessed by using the two-tail unpaired 
Student's t test. The differences between the means were accepted as 
statistically significant at the 95% level (p = 0.05). 
 
 
 
RESULTS 
 
Real-time PCR and Western blot experiments were performed to evaluate 
some of the genes involved in the DYRK1A/DSCR1/NFAT pathway. In 
particular, by Real-time PCR we observed a significant upregulation of 
DYRK1A, DSCR1 and NFATc4 (about 2 fold increase) and a 
downregulation of NFATc2 (69%) and NFATc1(49%) expression profiles in 
DS compared to controls (Fig. 2). No different expression was observed for 
NFATc3. To evaluate the levels of their relative proteic products, we 
performed Western blot experiments that confirmed the significant reduction 
of NFATc2 and the increase of DYRK1A and DSCR1 also in DS total 
protein levels (Fig. 3), while no difference was observed for NFATc1, 
NFATc4 and NFATc3 proteins. 
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To assess if the overexpression of DYRK1A and DSCR1 could influence the 
NFAT nuclear localization, we performed Western blot experiments on 
cytosolic and nuclear fractions after induction of lymphoblastoid cell lines 
with Calcium flows through PMA / ionomycin. Results showed a reduction of 
the NFATc2 levels in DS nuclear fractions following stimulation, suggesting 
the presence of mechanisms acting to inhibit its translocation (Fig. 4 A, B).
  
 
 
 
Fig. 2 Relative quantification of genes involved in the NFAT pathway. Histograms show 
mRNA levels of pool of DS subjects versus controls (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NFAT PATHWAY 
* 
* 
* 
* 
* 
p<0.05 * 
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Fig. 3 Western blot of DYRK1A, DSCR1 and NFATc2 total protein levels and their relative 
densitometry 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 Western Blot of NFATc2 cytosolic and nuclear fractions with and without PMA and 
Ionomycin (10 ng/ml and 1g/ml respectively)  
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* 
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DISCUSSION 
 
The nuclear factors of activated T cells (NF-ATs) are member of a family of 
transcription factors that transduce calcium signals in the immune, cardiac, 
muscular, and nervous systems  
(Crabtree, 1999). NF-ATs are located in the cytoplasm of resting cells and are 
activated by calcineurin following calcium signalling that induces their 
movement into the nucleus. (Zhou et al., 2000). 
DYRK1A and DSCR1, located on the DS critical region and involved in 
mental retardation, were associated to the nuclear translocation of the NFAT 
factors in mice models of DS (Arron et al., 2006) and the 
DYRK1A/DSCR1/NFAT pathway was suggested as a candidate to have a 
role in the DS phenotype.  
In the present study we analyzed this pathway, in human lymphoblastoid cell 
lines from DS and controls, by Real Time PCR and Western blot 
experiments. 
As expected, results indicated that DYRK1A and DSCR1 genes are 
overexpressed of about 2-fold in DS cell lines compared to controls. For the 
NFATc transcriptor factors we found a downregulation of the NFATc2 and 
the NFATc1 gene and an up-regulation of the NFATc4 gene in DS subjects. 
Further analyses confirmed the significant increase of DYRK1A and DSCR1 
and the reduction of NFATc2 also at protein levels, while no differences were 
observed for the other NFATc members. 
When analyzed the cytosolic and the nuclear fractions after Calcium flows 
stimulation, we found a reduction of the nuclear translocation of NFATc2 in 
DS subjects.  
These results suggested that there is a deregulation of the NFAT pathway also 
in human DS lymphoblastoid cell lines, and confirmed that the 
overexpression of the two ch21 genes, DYRK1A and DSCR1, leads to the 
reduction of the NFATc2 nuclear export. 
Therefore the DYRK1A/DSCR1/NFAT pathway remains a strong candidate 
for the DS pathogenesis. 
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Chapter 5 
 
MCPH1 gene, a key regulator of brain development, is 
down-regulated in DS but is not mutated in primary 
microcephaly 
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INTRODUCTION 
 
The human brain develops from a swelling at the rostral end of the neural 
tube. Rapid and sustained cellular proliferation during fetal development is 
required to generate the brain, and especially the cerebral cortex whose 
surface area has increased over a thousand fold during mammalian evolution, 
to accomodate the brain within the skull. The cerebral cortex must fold to 
assume an invaginated, convoluted appearence with gyri and sulci. 
Microcephaly is a term denoting a reduced head circumference greater than 3 
standard deviations below the mean (-3 s.d.) having multiple aetiologies, both 
genetic (nonsyndromic, syndromic or chromosomal) and environmental (eg. 
perinatal asphyxia, and intrauterine infection). 
Microcephaly is a common feature observed in more complex genetic 
disorders that additionally confer growth delay (Down syndrome and Di 
George syndrome) but could be also present also in patients that exhibit 
solely a reduced cerebral cortex, without other developmental abnormalities 
or neurological deficits, aside from mental retardation (Autosomal recessive 
Primary Microcephaly). In this case brains, although very small (typically -4 
to -12 s.d.), exhibit normal cortical architecture, suggesting that microcephaly 
is a consequence of reduced cell number either as a result of reduced 
neuroprogenitor division or increased apoptosis during neurogenesis. 
(Mochida and Walsh 2001). 
 
 
 
1.  MCPH1 gene 
 
MCPH1 was the first causative gene of primary microcephaly identified 
(Jackson et al., 2002). It was described in 2 linked Pakistani families, as a 
gene mapping on chromosome 8 (8p22-pter), consisting of 14 exons encoding 
a protein of 835 amino acids termed microcephalin. The antisense strand of 
intron 12 contains the angiopoietin 2 gene. 
Microcephalin, contains 3 BRCT domains (C-Terminal domain of a Breast 
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cancer susceptibility protein), known to be present in several key proteins 
involved in the cell-cycle regulation and DNA repair (Huyton et al., 2000), 
and it is mainly expressed in brain, kidney and fetal liver and at low levels in 
other fetal and adult tissues . In situ hybridization study of mRNA from fetal 
mouse sections have revealed the expression of microcephalin in the 
developing brain. 
As predicted by the presence of the BRCT domains, Xu et al., (2004) showed, 
in human embryonic kidney cells, that MCPH1 is involved in the response to 
DNAdamage, such as double-strand breaks (DSBs, double strand breaks) 
induced by ionizing radiation, and control of cell cycle progression, 
particularly at the transition G2/M, by adjusting the BRCA1 and Chk1 
(Checkpoint Kinase 1) levels. In addition, Alderton et al., (2006) found a 
defective G2/M checkpoint arrest, nuclear fragmentation after DNA damage, 
and supernumerary mitotic centrosomes in human lymphoblastoid cell lines 
with different truncating mutations in MCPH1. By coordinating the input 
stage of mitosis during the cell cycle, MCPH1 has an important effect in the 
process of proliferating neural cells. 
 
 
2. MCPH1 and Down syndrome 
 
Microcephaly is a common features oserved in subjects with Down syndrome 
(DS), the most frequent genetic cause of mental retardation. 
DS brain is characterized by a reduced cerebellar volume and number of 
granular cells, defective cortical lamination and reduced cortical neurons, 
malformed dendritic trees and spines, and abnormal synapses. These 
neurological alterations, cold result both from the dosage effect of some 
Human Chromosome 21 (HC21) genes and from their infuence on the 
expression of critical developmental genes. 
A previous transcriptome analysis permormed by our group on DS 
lymphoblastoid cell lines by using DNA microarray (Affymetrix HU133 plus 
2.0 oligonucleotide arrays), allowed us the screening of about 38,500 well 
characterized human genes with the aim to identify molecular changes 
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associated to some DS phenotypes. 
Interestingly, finding deregulations of genes that may lead to defective 
neuronal circuits in DS pathogenesis, the MCPH1 gene was found strongly 
down-regulated. (p<0.01 FC 0.69). 
 
 
3. MCPH1 and autosomal recessive microcephaly 
 
Autosomal recessive primary microcephaly (MCPH, OMIM 251200) is a rare 
non-syndromic congenital microcephaly inherited as an autosomal recessive 
trait. The incidence of MCPH ranges between 1:30,000 and 1:2,000,000 in 
non-consanguineous populations, as compared to 1:10,000 in consanguineous 
northern Pakistani families (Woods et al., 2005). Distinct subtypes of MCPH 
have been described: microcephaly vera (MV), microcephaly with simplified 
gyral pattern (MSG) and microlissencephaly (MLIS) (Barkovich et al.,2005). 
Before the discovery of the genetic bases of MCPH, these disorders were 
phenotypically defined by strict diagnostic criteria such as (1) congenital 
microcephaly at least 4 SD below age and sex means; (2) mental retardation; 
(3) absence of other neurological findings including spasticity, seizures or 
progressive cognitive decline; (4) normal height and weight; (5) absence of 
chromosomal aberrations; (6) no dysmorphisms and brain malformations 
(Jackson et al., 2002; Roberts et al., 2002). 
To date, seven loci (MCPH1-MCPH7) have been mapped with seven 
corresponding genes ((MCPH1, WDR62, CDK5RAP2,CEP152, ASPM, 
CENPJ,and STIL) identified from different world populations.  
The ASPM gene at MCPH5 locus and the and WDR62 gene at MCPH2 locus 
are the most frequent genetic cause of MCPH being mutated in about 55-60% 
of the MCPH families jointly (Roberts et al., 2002; Nicholas et al., 2009; 
Nicholas et al., 2010; Mahmood et al., 2011); while MCPH1 mutations account 
for 4% of cases in consanguineous Pakistani families (Roberts et al., 2002; 
Woods et al., 2005). Mutations of other genes are even rarer. For MCPH1, the 
following homozygous gene mutations have been described so far: a nonsense 
mutation in Pakistani consanguineous families (c.74 C > G; p.S25X) (Jackson 
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et al., 2002), an insertion in a Lebanese family (c.427_428insA) (Neitzel et al., 
2002; Trimborn et al., 2004) and a missense mutation in a Caucasian patient 
likely descending from consanguineous parents (c.80 C > G; p.Thr27Arg) 
(Trimborn et al., 2005). Studies in unrelated patients are scanty. MCPH1 is also 
rich in polymorphisms, c.940G > C representing the most frequent one. Among 
patients with MCPH1 mutations, mild microcephaly, short stature, and 
periventricular neuronal heterotopias have been reported (Neitzel et al., 2002; 
Trimborn et al., 2004; Trimborn et al., 2005; Garshasbi et al.,2006). Seizures 
have been rarely described (Woods et al., 2005). 
 
 
 
OBJECTIVE 
 
MCPH1, the first causative gene of primary microcephaly identified, was 
found significantly down-regulated in a population of subjects with Down 
syndrome, in whom syndromic microcephaly has been described. 
Since MCPH1 mutations are associated to autosomic recessive primary 
microcephaly and account for 4% of cases in consanguineous Pakistani 
families (Roberts et al., 2002; Woods et al., 2005) but studies in unrelated 
patients are scanty, we analyzed the sequence of the entire gene to identify 
the presence of molecular changes in a population of eighty-one unrelated 
patients with primary micricephaly from different ethnic groups. 
 
 
 
MATERIALS AND METHODS 
 
Patients 
Eighty-one unrelated patients (78% Caucasian, 16% Arabs, 6% otheI) were 
enrolled in the study (81.5% MV, 17.3% MSG, 1.2% MLIS). Patients were 
divided in two groups: group 1 including 34 patients meeting the strict MCPH 
criteria (Woods et al., 2005); and group 2 including 47 patients meeting the 
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expanded MCPH criteria (microcephaly ≤−2 SD at birth and <−3 SD at 
inclusion (after 1 year of age) and brain malformations) (Passemard et al., 
2009b). All patients had microcephaly at enrollment, with an OFC ranging 
from −3 to −8 SD, and had no ASPM mutations. Written informed consent 
was obtained from all patients or their guardians and ethics approval was 
given by the host institutions. 
 
DNA extraction and sequencing 
DNA was extracted from peripheral blood samples by salting out according to 
Miller and coworkers instructions (1998) or by using Qiagen kit (Qiagen, 
Hilden, Germany) and a DNA pre-amplification Genomiphi kit (GE 
Healthcare Biosciences AB, Uppsala, Sweden) according to the 
manufacturer's recommendations. Sequence analysis of the 14 exons and 
exons/introns boundaries of the MCPH1 gene was performed using 19 primer 
pairs (table 1), exon 8 was divided into 6 fragments (AF). PCR conditions 
were variables depending on the primer sequences and the relative products 
were first purified, by using QIAquick PCR purification Kit (Qiagen) or Exo-
SAP-purification system (Roche), and then sequenced by using Big Dye 
Terminator Ready Reaction Kit (PE Biosystem). Sequences were purified by 
Centri-Sep Columns and loaded on ABI PRISM 377 (Applied Biosystems, 
Foster City, CA). Sequences were compared with a control DNA and a 
reference cDNA sequence (GenBank accession: AX087870).  
 
Statistical analysis 
 For statistical analysis, chi-square test was used to compare categorical data 
(EpiInfo version 3.3, 2004). To correct for inflated alfa error, the modified 
Bonferroni test provided by Keppel was used (Keppel, 1991). The adjusted P-
value was considered as the new cut-off to determine statistical significance 
(adjusted P-value: 0.04). Z-score was used to compare the proportion of 
MCPH1 mutations in the 81 MCPH patients (zero mutations) to the 
proportion of mutations in consanguineous families (4%). 
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Table 1 : Primers used for sequence analysis of the MCPH1gene 
 
EX FORWARD REVERSE 
1 5’-GAGAAATCCCGGAAACGCGG-3’ 5’-CGAGTGCGCCCGCGACGAGG-3’ 
2 5’-GCGTGAGCCCATGTGCCGGC-3’ 5’-CGCTTACCCATTGCTTCGTCCAG-3’ 
3 5’-CGAGCGTTATGCATTCCTTTGAG-3’ 5’-GCTTCAGGACCTGCAGGCTCC-3’ 
4 5’-CCTGCCTCTTGCTTCTGTTAT-3’ 5’-GCTATCGAAGAAGTCATAGG-3’ 
5 5’-GCGAAAGGGCTTTTTCTCCTGCC-3’ 5’-GAACCCCACTAGTCATCATCATGC-3’ 
6 5’-GCAGGAGTAGGTAATGATGTTG-3’ 5’-CCATAATTGAATCGGCTATTTGC-3’ 
7 5’-CTTCCTGCTGGCTTCATCTGC-3’ 5’-CTCATCAGAAGTTGCTACATG-3’ 
8A 5’-GGAAATGAGAAGAACTCAAGTGTGG-3’ 5’-CGAGGTGAGTGAAAGATGGTG-3’ 
8B 5’-GGAAAGGAAGTTGGAAGGATCC-3’ 5’-CTTCGGAGGTGAATGGGAGC-3’ 
8C 5’-CCTTATCTTCAACAAAAGGCC-3’ 5’-CCTTCTTAGAAAGACTTCTGCAGC-3’ 
8D 5’-GCTGTGGGCAGTCTTCATATG-3’ 5’-GCTTCTTCAGGGGCAGAAGTCACG-3’ 
8E 5’-GCAAAAACCATCTCCAGTCC-3’ 5’-GCTCATGTTCACTCTGGGCTTCGC-3’ 
8F 5’-GCGGTTGGTCTGAAAAGCAC-3’ 5’-CCACAAGACAGCAAGTCATCTATTCC-3’ 
9 5’-GCTTAAGTTGTATTTGGTCCATG-3’ 5’-GGTTTATGTTTCATTGACCC-3’ 
10 5’-GCTTTGGGGACAGTATCTGAG-3’ 5’-GACAAGTTGCCTAAAGGCACCC-3’ 
11 5’-GCTTTGATGGGCATGTGCAAC-3’ 5’-GCTGATGTCGGCACCTCAGG-3’ 
12 5’-GCGGAGTGTATCACTTTTTGC-3’ 5’-GGGCATAATTGTGCTTGACTGG-3’ 
13 5’-CTGCAACAGTTCGCCTACGC-3’ 5’-CTGGAAACCTGTCCACAGATCTGG-3’ 
14 5’-GCCTATGGACAACACAGCTCTTGG-3’ 5’-CCTATGAGTTCTTAAGAACC-3’ 
 
 
 
RESULTS 
 
As expected, the molecular analysis of MCPH1 revealed that this gene is 
highly polymorphic with exon 8 and 13 particularly rich in known genetic 
variants. In particular, the c.790A > G, c.863C > A, c.911G > T, c.940G > C, 
c.1175A > G, c.1428C > T, and c. 1782G > A polymorphisms were found in 
exon 8, while the c.2226C > T, c.2282C > T, and c.2418C > A 
polymorphisms were found in exon 13. Other polymorphisms: c.228G > T, 
c.513G > T, c.2045C > A, c.2466G > A, and c.2482C>T were found in exons 
3, 6, 11, and 14 respectively. (Table 2). 
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Table 2.: Results of the molecular analysis of the MCPH1 gene on 74 patients. 
 
Gene Protein Exon 
c.228 G>T p.V76V 3 
c.513 G>T p.R171S 6 
c.783 T>A * p.D261E 8 
c.790 A>G p.I264V 8 
c.859 A>C * p.S287R 8 
c.863 C>A p.P288H 8 
c.911 G>T p.R304 I 8 
c.940 G>C p.D314H 8 
c.989 A>G * p.Y330C 8 
c.1175 A>G p.D392G 8 
c.1782 G>A p.T594T 8 
c.1428 C>T p.F476F 8 
c.2045 C>A p.T682N 11 
c.2226 C>T p.S742S 13 
c.2282 C>T p.A761V 13 
c.2418 C>A p.A806A 13 
c.2466 G>A p.Q822Q 14 
c.2482 C>T p.P828S 14 
* new mutations 
 
 
No pathogenetic mutations were found in both groups analyzed, but three 
novel sequence variations in the heterozygous state were found in exon 8: the 
c.783T > A transition, causing a synonymous substitution of an aspartic with 
a glutamic acid residue at position 261 (p.D261E); the c.859A > C 
transversion, causing the change of a serine with an arginine at position 287 
(p.S287R); the c.989A > G mutation, causing the substitution of a tyrosine 
with a cysteine at position 330 (p.Y330C).  
The new mutation c.783 T>A was found in a patient and his sister in 
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combination with the polymorphism c.940 G>C in the homozygous state, 
while the other two new mutations were found in one patient associated to the 
c.940 C>G polymorphism in the heterozygous state. 
 
 
 
DISCUSSION 
 
Microcephaly is a congenital reduction in brain size greater than three 
standard deviations (S.D.) below the age-related mean, that could be 
syndromic, in association to other features of more complex pathologies such 
as Down syndrome; or nonsyndromic, in which patients exhibit solely a 
reduced cerebral cortex without other developmental abnormalities or 
neurological deficits aside from mental retardation. 
Primary microcephaly (MCPH, OMIM 251200) is a rare non-syndromic 
congenital microcephaly inherited as an autosomal recessive trait and 
MCPH1 (microcephalin) was the first causative gene identified.  
Microcephalin is implicated in DNA damage induced cellular responses, 
chromosome condensation and cell-cycle regulation, and was suggested as a 
key player of neural proliferation and brain development. 
In agreement, our previous transcriptome analysis revealed that in a 
population of DS subjects, affected by a syndromic form of microcephaly, the 
MCPH1 gene was significantly down-regulated. 
The sequence analysis of the entire gene in a non-consanguineous 
heterogeneous population instead, did not identified causative mutations of 
MV. Only, three new gene variants were found, two of wich in the same 
patient and associated to another yet known polymorphism. 
In conclusion, MCPH1 may be associated to brain development in DS 
subjects, but it is not involved in the pathogenesis of MV in a large cohort of 
Caucasian patients and from NorthAfrica . 
A possible role of a combination of certain gene variants in the pathogenesis 
of microcephaly vera remains to be determined. 
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